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ABSTRACM 
The purpose of this study was to classify oral squamous cell carcinomas (OSCCs) based 
on their gene expression profiles, to identify differentially expressed genes in these 
cancers, and to correlate genetic deregulation with clinical-histopathological data and 
patient outcome. After conducting proof of principle experiments utilizing six head and 
neck squamous cell carcinomas (HNSCCs) cell lines, the gene expression profiles of 20 
OSCCs and subsequently an additional 8 OSCCs were determined using cDNA 
microarrays containing 19,200 sequences and the Binary Tree-Structured Vector 
Quantization (BTSVQ) method of data analysis. Two sample clusters were identified in 
the group of 20 tumors that correlated with T3-T4 category of disease (P=0.035) and 
nodal metastasis (p=0.035). Sample clustering of 28 OSCCs and the 6 cell lines revealed 
a correlation with disease free survival. BTSVQ analysis identified a subset of 23 
differentially expressed genes with the lowest quantization error scores in the cluster 
containing more advanced stage tumors from the 20 OSCC dataset. The expression of six 
of these differentially expressed genes was validated by quantitative real-time RT-PCR. 
Statistical analysis of quantitative real-time RT-PCR data was performed and, after 
Bonferroni correction, CLDNI (p = 0.007) over-expression was significantly correlated 
with the cluster containing more advanced stage tumors. Despite the clinical 
heterogeneity of OSCC, molecular subtyping by cDNA microarray analysis was able to 
identify distinct patterns of gene expression associated with relevant clinical parameters. 
The application of this methodology represents an advance in the classification of oral 
cavity tumors, and may ultimately aid in the development of more tailored therapies for 
oral carcinoma. 
2 
TABLE OF CONTENTS 
ABSTRACT . ................................................................................................................................. 2 CHAPTER 1: introduction to Head and Neck Cancer .................................................................. .5 1.1 Aetiology: ................................................................................................................. 5 
1.2 Family History: ......................................................................................................... 8 
1.3 Molecular Genetics of head and neck cancer: .......................................................... 9 1.3.1 Cytogenetic abnormalities, tumor suppressor genes and oncogenes: ................ 9 
1.3.2 Growth factors: ................................................................................................ 12 
1.3.3 Telomeres and telomerase: .............................................................................. 
13 
1.3.4 Molecular Progression: .................................................................................... 13 
1.3.5 Tumor Immunology: ........................................................................................ 13 
1.3.6 Angiogenesis: ................................................................................................... 14 
1.4 Clinical applications ................................................................................................ 15 CHAPTER 2: Introduction to microarrays ................................................................................... 17 2.1 Introduction ............................................................................................................. 
17 
2.2 Microarray Technology: ......................................................................................... 17 
2.3 Bioinfon-natics ......................................................................................................... 19 2.3.1 Gene Expression Data Characteristics . ............................................................ 20 
2.3.2 Gene Clustering ............................................................................................... 21 
2.3.3 Binary Tree Structured Vector Quantisation ................................................... 22 
2.4 Applications ............................................................................................................ 25 
2.5 Microarrays in head and neck cancer ...................................................................... 28 
2.6 Consolidating microarray data ................................................................................ 30 CHAPTER 3: Gene expression profiling of HNSCC cell lines and Oral Squamous Cell Carinoma 
tumor samples ............................................................................................................................ 31 3.1 Introduction: ............................................................................................................ 31 
3.2 Material and Methods: ............................................................................................ 34 
3.2.1 Cell Lines ......................................................................................................... 34 
3.2.2 RNA isolation from cell lines .......................................................................... 34 
3.2.3 Tumor Samples: ............................................................................................... 35 
3.2.4 RNA isolation from tumor samples: ................................................................ 
36 
3.2.5 Patient Information: ......................................................................................... 37 
3.2.6 cDNA Microarrays ........................................................................................... 38 
3.2.7 Labeling of cDNA and Hybridization to Arrays .............................................. 
38 
3.3 Data collection ........................................................................................................ 42 
3.4 Bioinformatics ......................................................................................................... 44 
3.5 Statistical analysis of sample clusters ..................................................................... 46 
3.6 Results: .................................................................................................................... 
47 
3.6.1 Gene expression analysis of 6 HNSCC cell lines: ........................................... 47 
3.6.2 Gene expression analysis of 20 OSCCs: .......................................................... 47 
3.6.3 Gene expression analysis of 6 HNSCC and 28 OSCC samples: ..................... 50 
3.7 Discussion ............................................................................................................... 52 CHAPTER 4: Identification and validation of differentially expressed genes ............................... 64 4.1 Introduction: ............................................................................................................ 64 
4.2 Methods: ................................................................................................................. 66 
4.2.1 Gene identification: .......................................................................................... 66 
4.2.2 Validation by Quantitative Real-Time RT-PCR: ............................................. 
66 
4.2.3 Genes and Primers: .......................................................................................... 67 4.2.4 PCR Amplification: ......................................................................................... 67 
4.2.5 Quantitative Real-Time RT-PCR Data Analysis: ............................................ 68 4.2.6 Statistical Analysis of Quantitative Real-Time RT-PCR Results: ................... 69 
4.3 Results: .................................................................................................................... 71 
3 
4.4 Discussion ............................................................................................................... 74 4.5 Conclusions ............................................................................................................. 84 Acknowledgments 
.................................................................................................................... 85 REFERENCES: 
.......................................................................................................................... 86 FIGURES ................................................................................................................................... 98 Figure I 
......................................................................................................................... 98 
Figure 2: 
........................................................................................................................ 99 
Figure 3: 
...................................................................................................................... 100 
Figure 4 
....................................................................................................................... 101 
Figure 5 
....................................................................................................................... 102 
Figure 6 
....................................................................................................................... 103 
Figure 7 
....................................................................................................................... 104 
Figure 8 
....................................................................................................................... Jos 
Figure 9 
....................................................................................................................... 106 
Figure 10 
..................................................................................................................... 107 
Figure II..................................................................................................................... 108 
TABLES: ................................................................................................................................... log 
Table I......................................................................................................................... 109 
Table It: 
....................................................................................................................... 110 
Table III 
...................................................................................................................... III 
Table IV 
. ..................................................................................................................... 112 
Table V: 
...................................................................................................................... 113 
Table VI ...................................................................................................................... 114 
Table VII 
..................................................................................................................... 115 
Table Vill .................................................................................................................... 116 
Table IX ...................................................................................................................... 117 
Table X 
........................................................................................................................ 118 
4 
CHAPTER 1: Introduction to Head and Neck Cancer 
Cancers of the head and neck are the sixth most common cancers world wide., There is 
an increasing incidence in developing countries and in patients with no risk factors. 234 
The commonest histological type of tumor of the upper aerodigestive system is 
squarnous cell carcinoma (HNSCC). Rapid developments in the molecular biology of 
these tumors have made it increasingly clear that understanding the molecular and 
cellular evolution of these tumors is crucial to the clinical and surgical oncologist to 
improve diagnostics, treatment regimens and survival in patients with this lethal disease. 
1.1 Aetiology: 
Cigarette smoking and alcohol consumption are the two strongest aetiological factors for 
the development of HNSCC both independently and synergistical ly. 5 Smoking unfiltered 
cigarettes carries a slightly higher risk than filtered cigarettes. The dose dependant 
relationship between smoking and incidence of H`NSCC has been demonstrated in large 
autopsy and epidemiological studies, with the relative risk over non-smokers ranging 
from 2.4 for smokers of <7 cigarettes per day to 16.4 for smokers of >25 per day. 6 
However, cessation of smoking leads to a gradual reduction in risk by 70% after 10 
years. Carcinogenic epoxides, which bind to DNA, are produced by the action of aryl- 
hydrocarbon hydroxylase on methylcholanthine and benzanthracene, substances released 
by the burning of tar. 
The molecular genetic events caused by cigarette smoking have been elegantly 
demonstrated by two studies. p53 tumor suppressor gene mutations were detected in 42% 
7 (54/129) of consecutive HNSCC in one study. However when the analysis accounted for 
social habits, p53 mutations were detected in the tumors of 58% of patients who smoked 
and consumed alcohol, 33 % of those who smoked but did not consume alcohol, and 
only 17% of those who neither smoked nor drank alcohol (p = 0.001). Another study 
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examining head and neck cancer cell lines showed that the p53 mutations were 
principally quanine and thymine transversions, a point mutation that can be affected by 
the interaction of DNA with benzopyrene. 8 
The association between alcohol and the development of upper aerodigestive tumors has 
proven more difficult to unravel. The most recent published study which analyzed this 
was a Danish population based study of 28 180 patients. 9 Over a follow - up period of 
13.5 years, compared with non - drinkers, subjects who drank 7- 21 units of beer or 
spirits but no wine had a relative risk of 3.0 of developing oropharyngeal or oesophageal 
cancer. However, subjects who drank a similar amount but who also drank wine as > 
30% of their total alcohol intake had a relative risk of 0.5. The relative risk for subjects 
who consumed >21 units of alcohol excluding and including wine were 5.3 and 1.7, 
respectively. It seems from this study that wine drinkers may be at a lower risk of 
developing upper aerodigestive tumors than drinkers who have a similar intake of beer 
and spirits. 
Given the strength of the causal relationship between chemical carcinogens and the 
development of HNSCC, a superfamily of enzymes known as the glutathione S- 
transferases (GstP), responsible for the detoxification of a wide range of xenobiotics, 
have been implemented as a pivotal role in HNSCC turnorgenesis. 10 Mice with a "knock 
out" deletion of the pi-class glutathione S-transferases had a four - fold increase in the 
development of skin papillomas after exposure to polycyclic aromatic hydrocarbon 7,12- 
dimethylbenzanthracene and the tumor-promoting agent 12-0 -tetradecanoylphorbol- 13- 
acetate. " In humans, increased expression of GstP has been reported in many tumors 
including oral cancers. 12 An important member of this family of enzymes, GstPl, is 
polymorphic in humans with allelic variants showing differences in their catalytic 
activities towards a range of carcinogens. It has been suggested that the carriage of one 
of the less active allelic variants might result in increased cancer susceptibility in an 
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individual. Indeed, it has been shown that individuals with oropharyngeal and laryngeal 
cancers were associated with significantly lower frequency of GstP1 AA polymorphism 
than controls, suggesting that the polymorphism at GstP1 may mediate susceptibility to 
these cancers. 13 
The observation of synchronous and metachronous tumors in the upper aerodigestive 
system has given rise to the concept of "field cancerisation", a term coined to account for 
the presence of multicentric oral cancer. Various molecular studies have looked at 
whether this is the mechanism underlying the development of multiple primaries, or 
whether multiple primaries share the same clonal origin, but has subsequently migrated 
through the epithelium and later developed distinct genetic alterations such as in the case 
of multiple bladder tumors. 14 The detection of mutations and the overexpression of 
growth factors in histologically normal mucosa distant from the primary tumor tend to 
support the field cancerisation theory. 15 
Human Papilloma. Virus (HPV) and Epstein - Barr virus (EBV) have principally been 
implicated in the pathogenesis of head and neck cancers. The E6 and E7 regions of high 
risk HPV types (6,18 and 33) have been shown to inactivate the tumor suppressor gene 
products p53 and pRb, potentiating neoplastic change and cell immortal isation. 16 Using 
polymerase chain reaction (PCR)-based analysis, HPV DNA has been detected in 15 - 
62% of HNSCC. 17 Although the EBV has been detected in other head and neck cancers, 
EBV is especially associated with the development of nasopharyngeal carcinoma. Its 
genome is consistently found in nasopharyngeal tumor cells. Raised serum 
immunoglobulin A (Ig A) against the viral capsid antigen has been shown to precede 
clinical symptoms in nasopharyngeal cancer and the evidence suggests that patients in 
high risk regions with an elevated serum anti - EBV TgA level should have an 
endoscopic examination of the nasopharynx and blind biopsies to include the pharyngeal 
recesses. 18 
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Site-specific carcinogens have been identified for some head and neck cancers. Nickel 
and chromate dust are principle inorganic chemicals which can cause lesions in the nose, 
larynx, lung and paranasal sinuses. 19 Clusters of cases in the hardwood industry led to 
the identification of hardwood dust as an aetiological factor in the development of 
20 adenocarcinomas of the paranasal sinuses. Similar epidemiological evidence implicated 
nitrosamines in a salted fish diet below the age of ten in the development of 
nasopharyngeal carcinoma. 21 
The association of Patterson - Brown - Kelly syndrome (iron deficiency, glossitis, 
koilonychias and an upper oesophageal web) with postcricoid carcinoma may account 
for the relatively high incidence of both conditions in the UK and Scandinavia. This may 
also account for the fact that the postcricoid region is the only subsite of the 
hypopharynx where the incidence of carcinoma in women exceeds that of men and 
where the age of incidence is relatively young. The reported incidence of post - cricoid 
carcinoma in patients with oesophageal web is 4- 16%. The decrease in prevalence of 
Patterson - Brown - Kelly syndrome in Sweden as a result of dietary changes and 
education has been mirrored by a similar fall in the incidence of post-cricoid carcinoma. 
1.2 Family History. 
Using multivariate analysis, a relative risk of 3.5 - 3.79 for HNSCC associated with 
family history has been demonstrated in a large case - controlled study from Brazi 1.22 
This risk rose to 7.89 in first-degree relatives of patients with multiple HNSCCs. 
Although the exact nature of the association is unclear, these findings do suggest that 
familial factors may be important in determining susceptibility to HNSCC. The high 
incidence of nasopharyngeal cancer in south - east China, coupled with its greatly 
increased incidence in first degree relatives of patients with nasopharyngeal cancer, has 
led to a linkage analysis pointing to a susceptibility gene near the human leucocyte 
antigen (HLA) cluster on chromosome 6p. 23 In vitro studies have demonstrated increased 
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mutagen sensitivity in 14NSCC patients with a family history of HNSCC and further 
increases in those with two or more affected first-degree relatives or patients with 
multiple HNSCC. 
1.3 Molecular Genetics of head and neck cancer. 
An imbalance of the equilibrium between growth promoting and growth restraining 
signal transduction, and natural cell loss caused by proto-oncogene activation and tumor 
suppressor gene inactivation leads to an unbalanced mitogenic signal and consequent 
aberrant cell proliferation. This concept of genetic alteration leading to neoplastic 
phenotype and subsequent clonal expansion is the basis of the "clonal evolution model of 
tumor cell populations". 
Recently, there has been an increasing wave of interest in the significance of apoptosis in 
the development of cancer and its treatment. The induction of apoptosis in untreated 
tumors is complex and may involve a number of factors including tumor necrosis factor 
- alpha and expression of the oncogenes c-myc and c-fos in certain circumstances. In 
malignant head and neck tumors, the mode of action of the proto - oncogene bc1-2 has 
been shown to be a novel one by inhibiting apoptosis rather than stimulating cell 
proliferation. 24 Ionising radiation induces apoptosis in normal tissues and tumors to a 
variable extent and is related to an increase in the level of wild - type p53 protein in the 
cell. A number of co-ordinated genetic alterations affecting cell turnover is therefore 
required to initiate tumor formation and progression. The challenge has been the 
identification of these genetic events and their correlation to known events in the 
histological progression of tumors from non-nal mucosa, through dysplastic changes to 
invasive carcinoma. 
1.3.1 Cytogenetic abnormalities, tumor suppressor genes and oncogenes: 
9 
Cytogenetic studies in solid tumors have been hampered by the difficulties in 
establishing short - term primary cultures and the erratically acquired chromosomal 
abnormalities in long-term cell lines that may have occurred in vitro, influenced by 
culture conditions. However, some studies have identified chromosomal areas in head 
and neck cancer consistently showing frequent breakpoints suggesting the location of 
putative tumor suppressor genes (including 3p2l, SqW, 8pI 1, l7p13 and 18q2) and gain 
or amplification implying the presence of putative proto - oncogenes at other sites 
(including 3q, 5p, 8q and I lql3 ). 25 
Chromosomal region 9p2I loss is the most common chromosomal aberration detected 
not only in head and neck cancer but in the majority of human cancers, occurring in over 
70% of head and neck cancers. 26 Positional cloning strategies led to the identification 
and characterization of pI 6 (MTS I or CDKN2) as a candidate tumor suppressor gene in 
this area. 27 However, inactivation of this gene by point mutations is uncommon. 
Homozygous deletion and hypermethylation of the 5' promoter are the predominant 
modes of gene inactivation. Further support for the key role ofp16 as a tumor suppressor 
gene is given by the nature of its function as a potent cyclin/cyclin-dependant kinase 
(CDK) inhibitor involved in the GI-S cell checkpoint of the cell cycle aswell as the 
demonstration that transfection of full length cDNA of p16 and p] 6,8 into head and neck 
cancer cell lines results in marked growth inhibition with cell cycle arrest in GI . 
28 An 
important aspect of 9p2I deletions is that it is one of the earliest genetic events in the 
pathogenesis of all the cancers in which it has been implemented, specifically, non-small 
cell lung cancer, bladder cancer and head and neck cancer. The implication of this is that 
detection of 9p2I deletion or p16 inactivation may have considerable potential in the 
definition of early and high-risk pre-malignant lesions. 
About 60% of HNSCC show 3p deletion, with the specific regions being 3pl4,3p2l. 3, 
3p22 and 3p25.29 3pI4.2 is a site of chromosome fragility across which the FHIT gene 
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has been cloned. Different groups have reported mutations and aberrant transcripts of the 
MIT gene in up to 65% of head and neck tumors. 30 However, the function of this gene, 
in particular to act as a tumor suppressor gene, remains unclear. 
Loss of heterozygosity at chromosome l7p13 has been shown in over half of HNSCC 
and often correlates with p53 inactivation. 31 While p53 mutations are detected in early 
preinvasive lesions of the head and neck, their incidence increases with tumor 
progression. However, research appears to uncover ever more facets to a gene whose 
function is intimately related to that of other tumor suppressor genes, proto-oncogenes 
and growth factors. What is known, however, is that wild type p53 protein has a critical 
role in inducing GI - arrest until repair has been affected; or if that is not possible, in 
directing the cell into an apoptotic state through transcriptional activation of such genes 
as p2I1TVAFI, mdM2 and hax. Certain mutations of the p53 gene result in p53 protein 
that is transcriptionally inactive and therefore unable to execute this function, leading to 
propagation of acquired genetic alterations and outgrowth of malignant clones. 
Allelic loss at l3q14 also occurs in over half of HNSCC. 32 The area of deletion includes 
the retinoblastoma gene (RBI) and is immediately adjacent to the hereditary breast 
cancer gene BRCA2. Immunohistochemical analysis of the RBI protein product and 
mutation analysis of BRCA2 in head and neck tumors showing loss of heterozygosity at 
l3q14 have discounted both of these known tumor suppressor genes as putative tumor 
suppressor genes inactivated in this area and imply the presence of another tumor 
suppressor gene in this region. 33 34 The exclusion of BRCA2 is of particular interest as 
there is evidence that BRCA2 families show an excess of laryngeal cancer. 
Consistent amplifications of I lql3 implicated PRADI (CCNDI or cyclin DI) as an 
important oncogene involved in 14NSCC pathogenesis. Further work has shown that 
amplification of IIq 13 is associated with increased expression of this gene. On a clinical 
level, PRADI overexpression correlates with tumor progression and is strongly 
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associated with reduced disease free survival in patients with operable head and neck 
cancer. 
3536 
The role of the ras family of oncogenes in HNSCC pathogenesis is unclear. While a high 
incidence of ras mutations has been reported in HNSCC in India, several studies have 
failed to support this in the Western world. This finding suggests that there may be a 
specific mutagenic effect of chewing tobacco or betel nuts upon the ras gene. 3738 
1.3.2 Growth factors: 
Polypeptide growth factors and their receptors mediate signals that stimulate cell division 
and growth in normal cells under physiological conditions. Over-expression of these 
growth factors and their receptors may promote pathologically excessive cell growth 
and, as such, they could be considered as protein products of proto - oncogenes, 
especially when oncogenic retroviruses carry genes (v-onc) showing strong homology to 
corresponding human genes (c-onc). An example of this is the homology between viral 
v-erbB and human epidermal growth factor receptor (EGF-R). Qualitative analysis of 
various growth factors in HNSCC at the DNA, mRNA and protein level has consistently 
demonstrated grossly elevated levels of epidermal growth factor (EGF), epidermal 
growth factor receptor (EGF-R) and transforming growth factor-a (TGF-a) in head and 
neck cancer as well as surrounding histologically non-nal mucosa. 39-41 
over-expression of other growth factors and their receptors, such as platelet-derived 
growth factor (PDGF), fibroblast growth factors (FGF-1, FGF-2) and fibroblast growth 
factor receptor (FGF-R), has been demonstrated in head and neck cancers. 42 The growth 
factor-like molecule HER-21neu has shown great promise in prognostic determination in 
breast cancer, while although these amplification have been shown in some HNSCC, it 
has failed to show any association with clinical parameters. 43 44 However, the growth 
factor receptors expressed on tumor cell surfaces are being extensively investigated with 
optimistic early results as tumor-specific targets for immunotherapy. 
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1.3.3 Telomeres and telomerase: 
Telomerase activity has been demonstrated in 80% of oral cancers and around 50% or 
oral leukoplakia. 45 46 While detection of telomerase activity in oral rinses from the head 
and neck cancer patients remain limited by technical problems of test sensitivity, the 
potential for antitelomerase drugs as a novel treatment remains promising. 47 
1.3.4 Molecular Progression: 
Fearon and Vogelstein 48 proposed the pioneering genetic progression model for 
colorectal tumorgenesis in 1990. Specific genetic alterations were allied to each step of 
the well-established adenoma-carcinoma sequence in colorectal. tumorgenesis. A similar 
model has been more difficult to establish in HNSCC but a number of models have been 
suggested by different groups from analyzing published allelotype data; 49 from 
microsatellite analysis of adjacent areas of histologically normal tissue, dysplasia, 
carcinoma in situ and invasive carcinoma; 50 51 and from similar microsatellite analysis of 
tissue from individual patients biopsied at different times. Theses are largely in 
agreement with each other. Progression from normal squamous epithelium to 
52 hyperplastic epithelium is thought to be due to overexpression of EGF and EGFR. 
Telomerase activation and p16 inactivation causes progression to dysplasia. PRAD-I 
amplification, p53 inactivation and 3p deletion causes progression to carcinoma in-situ, 
and 4q, 5q, 8p and 13q deletion cause further progression to invasive carcinoma. Over- 
expression of matrix metalloproteinase is thought to be involved in metastasis. 53-56 
1.3.5 Tumor Immunology: 
The successful development of a tumor depends on neoplastic cells escaping either 
recognition or destruction by the immune system. Such escape in HNSCC may arise 
from functional down-regulation of tumor infiltrating lymphocytes (TIL) by tumor- 
secreted factors such as prostaglandin E2 and TGF-p. 57 The identification of tumor 
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specific antigens has both diagnostic and therapeutic implications. The monoclonal 
antibodies E48 and U36 bind to peptides expressed in HNSCC, stratified epithelium and 
transitional epithelium. 58-60 Technetium-99m-label led E48 IgG has been used for clinical 
imaging of head and neck cancer6l while both E48 and U36, coupled with iodine-131 
and rhenium-186, respectively, have successfully been used for immunotargeting 
HNSCC in nude mice. 62 The clinical trial of immunotherapy showing the greatest 
promise in head and neck cancer has arisen from the observation that HNSCC cells 
secrete immunoregulatory cytokines which effect growth inhibition both directly and 
indirectly. Local treatment with IL-2 given by intratumoral injection in one trial of 
patients with recurrent HNSCC has been shown to give total or partial responses in 
around 30% of patients . 
63 This may be related to an increase in T-cells and lymphokine 
activated killer cells within the tumors. Systemic treatment with cytokines such as IL-2, 
IL-12 and interferons has been limited by treatment-associated toxicity. 11-2 has been 
used to expand TIL in vitro followed by reintroduction of autologous IL-2 activated 
TIL. 64 Although such cellular adoptive immunotherapy showed early promise in animal 
models, it has yet to be translated into full clinical trials. 
1.3.6 Angiogenesis: 
Angiogenesis has been demonstrated immunohistochernically in a number of tumors, 
including HNSCC, with antibodies to vascular antigens such as factor VIII-related 
endothelial antigen . 
65 Published data correlating the degree of tumoral microvessel 
density and clinical parameters in HNSCC is inconsistent, but there is good evidence that 
high microvessel density may predict a favorable response to radiotherapy, particularly 
in nasopharyngeal carcinomas. 66 Further promise for targeting angiogenesis comes from 
studies involving endostatin, an endogenous protein that is a potent inhibitor of 
endothelial cell proliferation, a process that underpins angiogenesiS. 67 Convincing animal 
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data has shown that endostatin treatment of mice with implanted tumors resulted in 
complete resolution without recurrence after two to six weeks of treatment. 68 
1.4 Clinical applications 
Perhaps the holy grail of the molecular oncologist is gene therapy. Even before the 
successful cloning of known tumor suppressor genes, a crude form of gene replacement 
therapy by introduction of whole chromosomes suspected of harboring putative tumor 
suppressor genes had been shown to suppress genes turnorigenicity in vitro. The 
introduction of wild type p53 and p16 into human head and neck cancer cells either by 
transfection in vitro or via a recombinant adenovirus in vivo in nude mice has 
consistently shown growth suppression in both circumstanceS. 69 Other genetic 
modulation treatments involve the use of virus-directed enzyme prodrug therapy 
(VDEPT). In head and neck cancer, this has been extensively investigated in 
experimental animal work. An example of this is the introduction of herpes simplex virus 
thymidine kinase gene into tumor cells, resulting in the expression of thymidine kinase in 
those cells and its conversion of gancyclovir into phosphorylated compound which halts 
DNA synthesiS. 70 This type of treatment can be combined with IL-2 immunotherapy, 
which exhibits synergistic effects in animal models. 
Recent advances in molecular biological research in cancer have improved our 
understanding of the genetic and cellular events underlying the development of cancers 
of the head and neck. Genetic determination of phenotype and prognosis in head and 
neck cancer will be more important and as more genes become identified and greater 
precision in such determination is achieved. Several cytogenetic breakpoints have been 
shown to be associated with radioresistance in vitro. Additionally, certain apoptotic 
markers show promise as indicators of resistance to chemotherapy. 7 1 As these become 
more defined, treatment strategies may be tailored to the tumor genotype. The 
identification of new genes and identification of the oncogenic process hold promise for 
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radical improvements to established methods of tumor evaluation and treatment as well 
as exciting new developments in novel therapeutic strategies. 
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CHAPTER 2: Introduction to microarrays 
2.1 Introduction 
The draft sequence of the human genome was published in 2001.72 Researchers have now 
begun to unravel the functional relevance of these data. Many tools have been developed 
to meet this goal of which cDNA microarrays are the most promising for large-scale gene 
expression analysis. Traditional methods of gene investigation in cancer have relied on 
identifying single genetic alterations associated with disease. The strength of microarray 
analysis lies in the ability to analyze the expression of thousands of genes 
simultaneously. This allows a representation of the genetic activity of one target sample 
with or without comparison to a reference. 73 To date, microarray technology has altered 
the way scientists are approaching cancer research and may be important in optimizing 
treatment and improving outcome of patients with head and neck cancer. Although still in 
its infancy, it is likely to have direct application to diagnosis and prognosis in the near 
future. 
2.2 Microarray Technology. 
Not all genes are expressed at the same time or at the same level in the genome. 
Furthen-nore, the regulation of a given gene in relation to other genes ultimately results in 
normal cell function. Therefore, high throughput techniques were developed to detect and 
quantify thousands of genes at the same time. This resulted in the ability to perform 
simultaneous gene expression analysis, or "global gene profiling". Microarrays are 
platforms on which thousands of gene sequences are printed. Fluorescently labeled 
cDNA sequences from the sample of interest are hybridized to these targets. The 
fluorescent intensity of each hybridized sequence in the array is then read. The scanner 
that records the intensity value is linked to custom digital image analysis software, which 
produces a color-coded image of the array, and a quantitative value is recorded for each 
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target gene. Intensity of fluorescence correlates with expression of the gene for which the 
spot codes. A schematic of the basic microarray protocol is shown in Figure 1. 
There are two ways in which microarray slides are manufactured. The main difference 
between these two techniques lies in the size and nature of the sequences used. In the first 
technique, a high-density array of 25mer oligonucleotides is synthesized in situ on a glass 
surface using combinatorial chemistry and photolithography. 74 75 Affymetrix (Santa 
Clara, CA) manufactures this commercially available array, named "GeneChip@". In this 
technology, 10 pairs of DNA sequences represent each gene. The ability to identify 
single nucleotide polymorphisms and mutations is the major advantage to using this 
arraY76, because it includes sequences presenting single base-pair differences or 
mutations. Lindblad-Toh et al. 77 performed a loss of heterozygosity (LOH) analysis of 
small-cell lung carcinomas using single polymorphism arrays. These arrays can be 
broadly applied to several fields of medicine and research such as medical diagnostics 
and pharmacogenomics. In addition, owing to the small sequence size, a greater density 
of probes is housed on the same array. Affymetrix has recently introduced arrays housing 
up to 40,000 sequences, as well as gene-specific arrays (e. g. "TP53 GeneChip@"). 
Further details can be found at www. affymetrix. com. The standard Affymetrix protocol 
uses 5-10gg total RNA as starting material, from which biotinylated cRNA is 
synthesized. The use of less total RNA (2gg of starting total RNA) has been reported 78 
with results equivalent to the lOgg required using cDNA arrays. Finally, these 
commercial arrays have high unit costs; however the production process ensures 
consistency between arrays with no technical variability. 
The other technique uses cDNA sequences of known genes and Expressed Sequence 
Tags (ESTs). ESTs are sequences that are identified as potential mRNA, isolated, 
catalogued and cloned. The assignment of one EST to a particular gene is often done by 
sequence similarity. In the cDNA microarray technique, sequences are amplified by the 
18 
Polymerase Chain Reaction (PCR) and printed onto glass microscope slides using high- 
precision robotics. The size of amplified sequences is variable (500-2000 base pairs). 
There are currently several types of cDNA arrays available from different research 
institutions. cDNA arrays from the Microarray Centre of the University Health Network 
(www. microarrays-ca) were used in these experiments. The human cDNA clone sets 
printed on the slides are from the IMAGE Consortium (http: //image. ilni. gov/). 
Other methodologies are in current use or development. Hybridisation of mRNA to probe 
sequences has been carried out on a spherical surface using glass beads as a substrate 
rather than a flat surface. Okamoto et al describe a method that uses the same technology 
found in inkjet printers to eject a microdroplet of oligonucleotides onto a glass surface. 79 
They fabricated a custom microarray using bubble jet technology and then used the 
microarrays to discriminate between 2 SCC cell lines. Other techniques, such as serial 
amplification of gene expression ( SAGE ), directly measure mRNA concentrations 
rather than the hybridization of mRNA to DNA probes. 
2.3 Bioinformatics 
Bioinformatics is defined as the application of computational techniques to biology, in 
particular to molecular biology. The goal is to provide computer-based methods for 
coping with and interpreting large volumes of diverse data obtained by high-throughput 
approaches. When applied to microarray experiments, it is a complex subject and 
represents a mathematical evaluation of vast amounts of gene expression data in order to 
decipher coherent gene and metabolic pathway function in a global sense. Computational 
methods, capable of accurately distinguishing between different biological or clinical 
categories, and identifying determining genes are needed to organize and interpret 
microarray data. Each quantified expression values must be first normalized before 
further computational programs are introduced. Subsequent to this various gene 
clustering algorithms are applied depending on the question to be answered. 
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2.3.1 Gene Expression Data Characteristics. 
Gene expression data distributions can best be described by multivariate GaussianS. 80 
Exploration of gene expression data sets is always problematic due to its inherent 
dispersion and missing values. 81 In order to apply a cluster analysis technique, it is 
important to explore the characteristics of gene expression data. The selection of a 
clustering technique should be based on how the technique relates to the characteristics 
of the data, and whether this technique is able to find any biologically significant 
clusters. 81 In experiments involving a test versus reference design, representing 
differentially expressed genes with a log ratio provides an equal spread between up- and 
down regulated genes, with a mean of zero for equally expressed genes. Although there 
are clear advantages to using log ratios to represent the normalized data, this introduces 
the problem of loss of information about the absolute gene expression level in the 
sample. This may represent a statistical shortcoming, since equal weights could be given 
to ratios that are based on widely different absolute levels of expression. The background 
intensity poses another set of issues to be addressed. First, there is no single established 
method for deciding what is the most appropriate area around the spot for measuring 
background. In addition, subtracting locally measured background from the spot intensity 
value can result in a nonsensical intensity measurement. 
Preprocessing of the original data using an appropriate normalization technique can 
minimize various types of errors. Normalization should account for the dye bias, both in 
labeling and detection efficiencies, and for the nonlinear relationship between dye 
81 intensity and expression level. It should also handle negative intensity values, which 
may result from background subtraction, as well as variance within and among 
experiments. In the worst case, normalization may introduce more error into the data than 
it removes (as is often the case with background subtraction), thus further decreasing the 
quality and reliability of the results. Normalize Suite software package 
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(www. utoronto. ca/cancyto) normalizes Cy5 and Cy3 fluorescence intensities with or 
without background subtraction, across the entire array as well as across individual sub 
grids. Additionally, preceding normalization, filters are applied to remove spots below 
user-specified thresholds for fluorescence intensity, foreground-to-background ratio, 
and/or spot diameter size. After normalization and filtering, duplicate spots are averaged 
together and saved to disk. Two or more replicates of an experiment can be grouped 
together as a project. Thus, upon normalization of replicate arrays of the same 
experiment, the saved non-nalized files are averaged together using the 'project' software. 
Experiments where the fluorophore-labeling has been reversed are easily integrated with 
existing data. Finally, the 'clusterp' software identifies all the project files and saves 
these in a format that can be used by the Eisen Cluster software package 82 
(http: //rana. lbi. gov) or other clustering systems.. 
There are many additional issues related to microarray data generation, with numerous 
potential sources of error from the biological and technical side. In addition, the 
concentration of cDNA used in hybridization is non-linearly related to the signal 
intensity 81, which complicates any experimental conclusions. However, these issues are 
beyond the scope of this chapter. 
2.3.2 Gene Clustering 
Current analysis of microarray data involves applying both statistical and machine 
learning techniques, such as hierarchical clustering, 2, self-organizing maps 83 or K-means 
clustering 84 to organize genes and patient samples into meaningful groups. These 
methods have been extensively used in most microan-ay studies. 95-88 Hierarchical 
clustering is an agglomerative approach widely applied to databases of gene expression 
profiles from patient samples. It can delineate clinically relevant patterns in diverse 
cancers. This method successively merges individual data points into a tree structure 
called a dendrogram, based on their similarity. 
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Self-organizing maps are well suited for exploratory data analysis and are considered 
superior to hierarchical clustering when analyzing data containing outliers and sources of 
systemic error. Partial structure is imposed on the data, and then adjusted according to the 
results. The input is the raw expression data, and the output is a series of maps 
representing gene expression. 
Other approaches, such as Bayesian clustering, require availability of prior distributions 
of the data, while K-means clustering requires that the researcher determine K, which 
specifies the number of clusters in the data. It is becoming clear that the high complexity 
of expression data poses a challenge to existing tools. It has been shown that a 
combination of diverse basic approaches is a suitable manner to analyze of microarray 
data. " Most existing tools have been developed for relational types of data, which 
typically have a large number of instances but low complexity. Thus, high complexity 
causes many existing tools to fail or provides outcomes with limited usefulness. New 
tools must be flexible enough to support the diverse tasks associated with clinically 
relevant genomic research 
2.3.3 Binary Tree Structured Vector Quantisation 
One novel approach to microarray data analysis is the Binary Tree-Structured Vector 
Quantization (BTSVQ) system 90. The algorithm uses self-organizing maps (SOM) 83 
and partitive k -means clustering 
84 in a complementary fashion. It applies the vector 
quantization and self-organization capabilities of SOMs to find significant gene centers 
in gene space, which is characterized by high dimensionality and a large number of 
clusters. BTSVQ uses the effectiveness of k -means in sample space, which is 
characterized by medium dimensionality and a low number of clusters. The SOM 
algorithm finds gene centers by vector quantization and places genes with similar 
expression in neighboring units in the two dimensional map grid. Thus, SOM preserves 
similarity relationship in gene space. This quantization and re-arrangement of genes 
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ensures that quantized genes would have similar expression for similar samples. Thus, 
the component planes of similar samples would look similar. BTSVQ superimposes 
results from the two complementary clustering approaches - the highest confidence in 
the clustering result is achieved when samples with visually similar component planes 
are placed in the same child of the cluster tree. 
Beacause of the inherent dispersion and skewness of microarray data, and its closeness to 
multivariate GaussianS80 , BTSVQ adopts an iterative partitive clustering approach which 
extends the TSVQ approach. 91 The algorithm partitions data using the standard k- 
means algorithm in sample space, where k is kept constant at 2. Iteratively applying the 
algorithm and using evaluation of variance as a stopping criterion it generates a binary 
tree. The SOM algorithm is then used to cluster the gene space. The cluster structure in 
gene space is visualized using component planes of the already computed SOM. An 
outline of the binary tree-structured vector quantization algorithm (BTSVQ) is given 
below. 
1. Binary Tree generation: 
(a) Start with the whole data set in a single cluster 
(parent). 
(b) Partition the data set (experiment space) into 
two subsets using standard k-means (simple 
Euclidean distance measure is used) 
(c) Compute variance of both subsets (children). 
41 If variance of parent from step Ia is less 
than the variance of child from step I b, stop 
further partitioning of that child. 
* Repeat step Ib for all remaining children, 
taking each child as a parent. 
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2. Visualization: 
(a) Generate component planes of SOM for all 
samples. 
(b) Arrange the component planes at nodes of the 
B-tree generated in step 1. 
92 Component planes of SOMs are the planes of Voronoi Tessellations , each representing 
a sample in a microarray experiment (i. e., gene expression profile of a tumor). Figure 2 
represents quantized gene expression visualizations by component planes of a SOM. A 
hexagonal map unit in a component plane represents a gene selected by the SOM 
algorithm, which is a center of a cluster in the data. The color of the map unit represents 
the expression value of the gene associated with that unit. Thus, similar gene expression 
profiles correspond to similar color patterns of the component plane. 
BTSVQ has been used to identify clinically relevant molecular sub-classifications of 
tumors from gene expression data. One analysis revealed a number of novel observations 
on the pathobiology of lung cancer, most importantly, the presence of molecular 
subtypes of non-small cell lung cancer correlating with differences in rates of tumor 
recurrence and disease-free survival not evident from agglomerative clustering of the 
same data. 89 The BTSVQ algorithm delineated a subgroup of patients using all available 
gene expression data. In this patient cluster, a significant proportion of selected patients 
were characterized by an early recurrence of disease, indicative of more aggressive 
tumor biology. 14/17 of these patients had evidence of early disease recurrence on 
clinical follow-up, compared to 2nin an analogous subgroup on the opposite arm of the 
cluster tree. 
This type of system is ideally suited to analyze data from genetically heterogeneous 
samples such as those obtained from Head and Neck Cancer. This data is often skewed 
with many outliers and variable expression values requiring greater computational input 
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to identify significant gene expression patterns. Genetic profiles for each sample are 
readily visualized in the SOM clustered at the nodes of the binary tree thus creating a 
simple and biologically intuitive way for interpreting microarray data. Additionally, this 
system has been shown to be less sensitive to preprocessing and normalization, and 
successfully revealed clinically relevant clusters in three large publicly available lung 
microarray data sets. 90 Tibshirani et at found that this type of clustering method 
successfully organized genes and experiments and generated useful and visible data 
organization. 93 
BTSVQ selects a unique set of genes that best discriminates each sample cluster 
positioned at each node of the binary tree. Selection is based on the gene quantization 
error (QE). This is the probability of the gene having a similar expression value across 
all samples in that cluster thus providing a measure of the ability of a gene to define 
clusters of samples. The lower the QE, the higher the probability. In conventional data 
analysis such as hierarchical clustering, genes that fall below a certain fold change of 
expression are excluded from the analysis, thus selecting only highly differentially 
expressed genes. Based on a Cox proportional hazards model, Wigle et at showed that 
many genes that were below a certain fold change were capable of class distinction 
between groups of lung cancer patients with early recurrence versus no recurrence. 94 
Thus gene selection by QE aims to avoid the biases introduced by arbitrary threshold 
values. 
2.4 Applications 
Microarrays can be applied to both research and clinical settings. Below are some areas 
where microarray analysis has already made an impact. 
Exl2ression profiling: 
Structure and function of cells and tissues is determined by the selective, differential and 
collective expression of many genes. Measurement of global RNA expression represents 
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a tissue state of activity and differentiation. This allows the direct comparison of genetic 
activity of cancer cells with their normal counterparts in any tissue. Global expression 
profiles allow us to build gene maps showing how genes are functionally related to each 
other within the genome. Ross et aL9-' have recently described the pattern of expression 
of 8000 genes in each of the 60 tumor cell lines used in the NCI screen for anticancer 
drugs. Each tumor type and its tissue of origin expressed distinctive gene subsets 
("molecular signatures"), which correlated with known function. Thus, for example, 
melanoma cell lines prominently expressed genes associated with melanin metabolism. 
This may help classify the lineages of complex clinical samples such as poorly 
differentiated tumors and metastases of unknown primary origin. 
Molecular Tumor Classification: 
Improvements in tumor classification are central to the development of novel and 
individualized therapeutic approaches. Histologically indistinguishable tumors often 
show differences in clinical behaviour, and subclassification of these tumors based on 
their molecular profiles may help to explain why these tumors respond differently to 
treatment. In a landmark study, Golub et al. 96 applied microarray technology to develop 
innovative classifications to leukaemias, using microarray analysis based on 
"neighborhood analysis" and the utilization of tumor class predictors. This strategy was 
able to distinguish between acute myeloid leukeamia and acute lymphocytic leukeamia 
without supervisory analysis. Other groups have also used gene expression analysis to 
classify, at the molecular level, breast tumors '97-99 B-cell lymphoma, 
100 cutaneous 
melanoma, 101 alveolar rhabdomyosarcoma 102 and lung adenocarcinoma. 103 104 Likewise, 
in a recent study analyzing molecular profiles of 50 nonneoplastic and neoplastic prostate 
samples, Dhanasekaran et al established signature expression profiles of healthy prostate, 
benign prostatic hyperplasia, localized prostate cancer, and metastatic prostate cancer. 105 
These studies established the feasibility of combining large scale molecular analysis of 
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expression profiles with classic morphologic and clinical methods of staging and grading 
cancer for better diagnosis and outcome prediction. 
Mutation detection: 
Human diseases are frequently associated with mutations that affect specific genes. For 
example, over 400 mutations have been found in the BRCAI gene. 106 These mutations 
can be detected by creating 25mer oligonucleotide arrays with large numbers of single 
nucleotide variations. This allows rapid and precise identification of mutations or 
variation in individuals, families or populations. This process could be scaled up to 
simultaneously identify mutations or variants in large fragments of the human genome. 
Pharmacogenomics: 
Microarrays offer a number of new approaches to drug development and the prediction of 
therapeutic efficacy. Many genes in a cell can affect its response to therapeutic agents, in 
relation to drug exclusion, resistance, metabolism and DNA repair. The study of gene 
expression and genetic variation may allow the characterization of each cell, tissue and 
tumor in terms of predicted drug sensitivity, drug toxicity and development of resistance 
to therapeutic agents. 107 This analysis of individual variation is the basis of the new 
science of pharmacogenomics. 
Gene copy number analysis: 
Many tumors contain abnormal copy number of genes through processes such as 
chromosomal and gene deletion, amplification and aneuploidy. Quantifying the number 
of gene copies per cell can be helpful in understanding a disease process. Pollack et al 
were the first to describe microarray-comparative genomic hybridization (CGH) based 
techniques using cDNA targets. 108 This methodology consists of hybridizing target 
sample genomic DNA to cDNA arrays to identify copy number imbalances. 109 Recently, 
high-resolution profiling using array-CGH was used to study gene copy number changes 
in human tumors such as schwannorna"O and neuroblastoma, "' and for detection of 
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occult micrometastatic tumor cells. 112 Microarray-CGH thus allows the study of copy 
number changes across the entire genome of any one sample. 
2.5 Microarrays in head and neck cancer 
Head and neck cancer is a disease of considerable mortality. The overall prognosis of 
patients has not changed significantly in the past decade, with the 5-year survival rate 
remaining static at approximately 50%. It is hoped that novel molecular advances such as 
microarray technology may help in the understanding of this disease and ultimately lead 
to improvements in diagnosis, treatment strategies and outcome. 
Microarray technology has recently begun to be used extensively in head and neck cancer 
research. Most studies relate to identification of differentially expressed genes between 
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non-nal and malignant tissue, or between known subtypes of the disease. Belbin et al. 11 
used hierarchical clustering to identify a subset of differentially expressed genes to 
classify 17 head and neck tumors. Overall, the molecular classification of these tumors 
was a better predictor of disease-free survival than clinical and pathological parameters. 
Villaret et al. 1 14 used a cDNA array consisting of 985 cDNA probes to analyze gene 
expression differences between 22 normal tissue and 16 frozen section samples of 
HNSCC from multiple sites. 13 genes were differentially overexpressed in the tumor 
tissue, four of which were previously unidentified. A larger set of genes was analyzed 
using five paired cases of normal vs. HNSCC. 115 They demonstrated differential 
expression of various oncogenes, tumor suppressor genes and other genes, many 
involving cell cycle regulation and cell signaling. Several of these have not been 
previously reported as differentially expressed in head and neck cancer. Leethanakul et al 
used a cDNA array housing 588 known human cancer-related genes and nine 
housekeeping genes to examine five LCM-derived normal and head and neck cancer 
samples. 116 Down regulation of cytokeratins and an increased expression of several signal 
transduction and cell cycle-regulatory genes were noted. Recently, Squire et al have 
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identified recurrent chromosomal alterations by CGH and SKY and correlated these with 
expression array analysis in head and neck tumor cell lines and primary tongue tumors. 117 
These and other studies clearly demonstrate the potential power and use of this 
technology. 
Despite its potential, microarray technology is still relatively new and expensive, thus 
limiting the type and extent of research possible. Initial experiments have been criticized 
as having no underlying hypothesis. Additionally, the choice of array may lead to the 
identification of many genes irrelevant to the disease. Furthermore, validation of genetic 
deregulation by alternative techniques, such as immunohistochemistry, tissue arrays, 
fluorescent in situ hybridization (FISH), quantitative real time PCR, Western or Northern 
Blot are crucial in adding credibility and confidence to the data generated using 
microarrays. 
Tissue arrays involve taking six cores of 5 pm tissue from at least one hundred paraffin 
embedded tumor samples, and using these to create a new paraffin block. Sections from 
this new paraffin block can then be cut and interrogated with antibodies to identify which 
tumors express the protein of interest. Issues relating to accurate tissue sampling, 
standardization of staining patterns and number of sections required from each tumor are 
still problematic, but this technique allows the detection of the protein product of genes 
of interest simultaneously in a large number of tumor samples and is thus very powerful. 
Quantitative real-time PCR relies on the quantitation of the expression level of one gene 
in tumor samples in comparison to a reference sample. A reference gene (e. g. ribosomal 
RNA, P-actin, GAPDH), which should not vary in transcript levels in different tissues or 
states of differentiation, is also used as an amplification control. PCR can be performed 
using fluorescent dyes or probes and allows a quantitative detection of specific product 
accumulation during each PCR cycle. Relative expression levels or gene copy numbers 
are directly related to the amount of starting target cDNA or DNA and are determined by 
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measuring the cycle number (Ct) at which fluorescence intensity becomes statistically 
significant. 
2.6 Consolidating microarray data 
Establishing a consensus on the best overall method of microarray analysis is likely to 
prove challenging. Variability in RNA extraction, choice of array, hybridization and 
labeling protocols, and analysis software leads to difficulty in comparison between 
studies conducted in different laboratories. When one combines this with the genetic 
heterogeneity of most solid tumors and the vast amount of information generated by 
microarrays, it is a concem that, instead of refining our current knowledge of functional 
genomics, we will in fact be unable to condense the information into a usable form. To 
help address this problem in head and neck cancer, the Head and Neck Cancer Genome 
Anatomy Project (www. cgap. nci. nih) has been established as a joint program between 
the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial 
Research (NIDCR). The aim of this Project is to create libraries of genes that are 
consistently expressed in tumors of the head and neck, which will therefore serve as a 
global reference for any investigator. This interactive website allows one to identify 
genes from the accession number (Unigene ID) and generates a large amount of 
information, including gene function, interacting pathways, and chromosomal 
localization. Genetic databases such as these will allow collation of all the raw data for 
effective evaluation and interpretation, thus assisting in multi institutional genomic and 
proteomic initiatives and collaborations. 
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CHAPTER 3: Gene expression profiling of HNSCC cell lines 
and Oral Squamous Cell Carinoma tumor samples 
3.1 Introduction: 
Oral squamous cell carcinoma (OSCC) is a subset of head and neck cancer. It is the 10th 
most common malignancy, comprising 2-3% of all new malignancies diagnosed in the 
United States. 118 Etiological factors include consumption of tobacco and alcohol, poor 
oral hygiene, nutritional deficiencies and possibly certain viruses. 119-12 1 Despite progress 
in treatment over the last few decades, the average five-year survival rate of 50% has 
remained unchanged resulting in approximately 13,000 deaths yearly in the United 
States. 122 This poor prognosis is associated with several factors including the high 
incidence of regional metastasis at presentation. 123 124 Additionally, the lack of suitable 
markers for early detection, late presentation, insensitivity to available treatment and our 
limited understanding of the molecular mechanisms responsible for this disease all 
contribute to poor outcome. 
Based on the hypothesis that metastatic potential is determined mainly by the genetic 
properties of the primary tumor, a number of genes have been studied in primary 
carcinomas in an attempt to determine biological markers that may aid in classification 
and prognosis. However, the molecular heterogeneity seen within individual diagnostic 
categories has meant that no potential marker identified thus far has proven to be a 
sufficiently strong indicator of treatment response or prognosis to be used in the clinical 
setting. 125126 
Disease staging is largely based on anatomical considerations gained from clinical 
examination and imaging techniques. Differences in treatment response and outcome of 
patients with stage-matched tumors suggest that the current staging systems are limited 
in their ability to predict loco-regional control and survival for head and neck cancer 
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patients. For example, even when the neck has been clinically staged as No (Le. no 
evidence of regional neck nodal disease) the incidence of micrometastases in 
127 128 
postoperative histopathological sections of neck dissections is approximately 30%. 
Accurate staging is therefore crucial to ensure that optimal therapeutic strategies are 
implemented in order to improve patient prognosis and survival. 
Recently, global gene expression profiles generated by cDNA microarray analysis have 
been used as a powerful tool to classify different types of human cancers. 9496 129 It has 
become possible to predict the subtype of the disease without previous biological 
knowledge of the tumor by using genes that best discriminate between different forms of 
the disease. Thus, correlations between the genetic profiles of HNSCC cell lines and 
primary OSCC samples with clinical parameters, including nodal status, may provide the 
basis for a molecular classification system. 130 
Several studies have used cDNA microarray analysis to classify HNSCCs according to 
their gene expression profiles, and to identify genes involved in tumor development 
and/or progression. 113-117 131 132 Despite all of these studies, there are still few molecular 
markers that are clearly associated with prognosis and disease mechanisms. In addition, 
many studies focus on individual genes and have not analyzed clusters of genes that are 
similarly under- or over-expressed in groups of samples. Such clusters of genes may be 
more clearly associated with disease mechanisms and/or clinical parameters. 
In this study, cDNA microarrays were used to classify 6 HNSCC cell lines, 20 OSCCs 
and subsequently a combination of the 6 HNSCCs and 28 primary OSCCs according to 
their gene expression profiles. Most microarray studies have been perforined using 
tumors from different sites in the head and neck. However, by analyzing a subset of head 
and neck tumors, the aim was to minimize the genetic differences that may be present in 
anatomically diverse tumors. To the author's knowledge, this was the first report of 
cDNA microarray studies that have used as many samples from the same anatomical site 
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in the head and neck. The results suggested that gene expression profiling could 
determine deregulation in multiple genes potentially associated with advanced stage 
disease. These findings may help to form the basis for a molecular classification of 
HNSCC, thus improving diagnosis, treatment and outcome for patients with this 
carcinoma. 
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3.2 Material and Methods: 
3.2.1 Cell Lines 
The cell lines UTSCC-9, UTSCC-24A, UTSCC-2413, UTSCC-34, UTSCC-60A and 
UTSCC-60B were provided by Dr. Reidar Gr6nman, Dept. of Otolaryngology, Turku 
University Central Hospital, Turku, Finland. Clinical data of patients from whom the 
tumor cell lines were derived are shown in Table 1. Two cell lines were derived from 
primary tongue carcinomas (UTSCC-9 and 24A), one was from a tonsillar carcinoma 
(UTSCC-60A) and one was from a supraglottic laryngeal cancer (UTSCC-34). Cell lines 
UTSCC-24B and UTSCC-60B were from neck nodal metastases of the primary tumors 
from which cell lines UTSCC-24A and UTSCC-60A were derived. 
3.2.2 RNA isolation from cell lines 
Cell lines were maintained in keratinocyte growth medium. Following aspiration of the 
media, cells were washed once with Phosphate Buffered Saline (PBS). 5mls of PBS was 
added and the cells scraped from the plate. The cell suspension was transferred to a 50 
ml polypropylene conical-bottom tube (Falcon Cat# 352070). The plate was washed 
with an additional Iml PBS and the suspension added to the tube. A pellet of cells was 
produced by centrifugation at 2,300 rpm for 3 minutes at 4*C and the supernatant 
discarded. 2ml TRIZOL per -2xl 07 cells (approximately one 150 mm plate of 
keratinocytes) was added to the pellet and the suspension passed through an 18 gauge 
syringe several times to disrupt the pellet. The sample was incubated at room 
temperature for 5 minutes. 0.4ml of chloroform (0.2ml/Iml TRIZOL) was added and 
shaken vigorously for I minute then incubated at room temperature for 2 minutes 30 
seconds. 
Cellular debris was removed by centrifugation at 4,000 rpm for 15min at 4'C. The 
supernatant was transferred to 1.2 ml microfuge tubes (0.5ml/tube) and an equal volume 
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of isopropranol added to precipitate the RNA. The sample was incubated at room 
temperature for 15 minutes then centrifuged at 15,000 rpm for 15 minutes to pellet the 
RNA. The supernatant was discarded and the pellet re-suspended in 70% ethanol. The 
RNA was stored in 70% ethanol at -201C until use. Prior to use, the sample was 
centrifuged at 15,000 rpm for 15 minutes at 4"C and the supernatant discarded. The 
pellet was re-suspended in diethylpyrocarbonate (DEPQ treated water for labeling. The 
quantity and purity of the RNA was evaluated as per the tumor samples. 
3.2.3 Tumor Samples: 
The initial analysis involved twenty oral cavity tumor samples. Subsequent to this a 
further 8 samples were obtained, increasing the study number to 28. All samples were 
obtained at the time of surgery from the Toronto General Hospital, Toronto, Ontario, 
Canada. Tissues were snap frozen in liquid nitrogen within 30 minutes of resection and 
stored at -80'C in a tumor bank. To avoid contamination from normal stromal tissue, 
corresponding H&E-stained sections were examined by a board certified histopathologist 
to confirm the presence of at least 80% tumor cells in representative sections. Many 
studies are now using laser capture micro-dissection (LCM). " 5 This technology increases 
sample purity and thus has the potential of generating more accurate gene expression data 
without stromal contamination. However, this technique harvests only a small amount of 
tissue and consequently only small amounts of RNA are obtained. RNA amplification 
techniques optimized for LCM samples have been commercially developed. Linear RNA 
amplification protocols have been used to amplify as little as lOng total cellular RNA, 
corresponding to the amount that can be obtained from 103_104 cel IS. 133 1 34 However, 
these techniques often do not result in representative amplification of all transcripts 
present in the original sample. Iscove et al. 135 described a rapid reverse-transcriptase PCR 
procedure that preserves RNA abundance relationships after amplification. 13 Other PCR- 
based amplification methods have been reported to retain the expression inforination for 
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most genes in microarray experiments. 136 137 Because of the limitations in laser capture 
microdissection, the possibility of inaccurate RNA amplification and the added time 
required to process the material in this way, the method of insuring purity of samples by 
examination of corresponding histological slides was thought to be satisfactory. Other 
studies have used this technique to procure pure specimens resulting in informative 
microarray data. 94 
3.2.4 RNA isolation from tumor samples: 
Tissues were homogenized and total RNA isolated by a single extraction method using 
an acid guanidinium thiocYanate-phenol-chloroform mixture. The method provides a 
pure preparation of undegraded RNA in high yield and can be completed within 4 h. It is 
particularly useful for processing large numbers of samples and for isolation of RNA 
from minute quantities of cells or tissue samples. 138 Following homogenization, 0.1 ml of 
2M sodium acetate (pl-14), Iml of phenol and 0.2ml of chlorofonn-isoamyl alcohol 
mixture (49: 1) were sequentially added, with thorough mixing by inversion after addition 
of each reagent. The final suspension was shaken vigorously for 10 seconds and cooled 
on ice for 15 minutes. The samples were centrifuged at 10,000g for 20 minutes at 4"C. 
The aqueous phase was transferred to a fresh tube, mixed with Iml of isopropranol, and 
then placed at -20" for at least I hour to precipitate RNA. Sedimentation at 10,000g for 
20 minutes was again performed and the resulting RNA pellet was dissolved in 0.3mls of 
0.2M sodium acetate, phenol and chloroform, transferred into a 1.5ml Eppendorf tube, 
and precipitated with Ivol of isopropanol at -20' for I hour. After centrifugation for 10 
minute at 4'C, the RNA pellet was resuspended in 75% ethanol, sedimented, vacuum 
dried (15 minute), and dissolved in 50VI of 0.5% SDS at 65* for 10 minutes. RNA was 
evaluated by spectrophotometry and by electrophoresis on a 1% denaturing 
formaldehyde agarose gel by measuring A260 and A280. RNA was prepared to a final 
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concentration of I pg/pL. RNA from all 28 tumor samples was found to be suitable for 
cDNA microarray analysis. 
3.2.5 Patient Information: 
Patient clinical data and tumor characteristics are described in Table 11. Since 
consumption of tobacco and alcohol are important etiological factors in the development 
of head and neck cancer, only patients with a history of smoking and alcohol 
consumption were included in the study. Additionally, patients with a prior history of 
treatment HNSCC (surgery, radiotherapy, chemotherapy) were excluded. Although 
human papilloma infection plays an etiological role in HNSCC development in 10 - 20% 
of cases, human papillornavirus analysis was not performed, as it was not the primary 
focus of the study. ' 39 This work was approved by the local Ethics Committee and 
informed consent was obtained from all the patients prior to sample collection. The 
tumor bank database was examined to obtain clinical and histopathological information 
for each patient, including age, sex, history of consumption of tobacco and alcohol, 
disease stage, recurrence and outcome. This was often incomplete, and so in addition, 
patients' notes were accessed from medical records and audited to ensure accuracy of 
data. Some follow up information was obtained from the Ontario Cancer Registry. Since 
the Toronto General Hospital is a tertiary referral center for the whole of Ontario, 
patients were often referred from remote areas of the state. They received treatment 
within the specialist head and neck unit and were subsequently followed up locally. 
Therefore, in selected cases, full outcome details were obtained from direct 
communication with local hospitals or patients' general practitioner. Tumors were staged 
according to the current TNM classification as recommended by the International Union 
Against Cancer (UICC, 2002). 131 
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3.2.6 cDNA Microarrays 
Human 19K2 and 190 cDNA microarrays were purchased from the Microarray Centre, 
Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. The 
19K clone set infon-nation is available at the website 
microarrays. ca/support/download. html-umanl9k3. zip. These arrays house 19,200 
features including 18,980 human cDNAs and 220 positive and negative control features. 
The sequences on the 19K microarray are arranged on two glass slides (parts A and B), 
each one containing 32 sub grids with 24x25 features spotted over an approximate area 
of 18 x 36mm 2. All features are placed in duplicate, for a total of 38,400 spots. Two 
series of microarray experiments, one using cell lines derived from HNSCC and the 
other using primary OSCC tumor samples were performed as described below. Sequence 
verification studies performed by the Clinical Genomics Centre, Toronto, Ontario, 
Canada, allowed identification by BLAST of a small percentage of cDNAs 
contaiminated with mitochondrial DNA. Identification of such sequences allowed 
appropriate filtering of features during data analysis. 
3.2.7 Labeling of cDNA and Hybridization to Arrays 
cDNA microarray labelling protocols involve either direct or indirect labeling of cDNA 
with fluorescent dyes. Direct labelling is a fast, one - step method, while indirect 
labelling is a two step procedure involving AAdUTP in the reverse transcription reaction 
to incorporate an amine-modified nucleotide and subsequent coupling with 
monofianctional forms of Cy3 and Cy5 dyes which will react with the amine-modiried 
cDNA. Indirect labeling uses less RNA, takes three days to process, and may give higher 
intensity spots. The direct labeling protocol (available from the Microarray Center of the 
University Health Network, Toronto, Ontario, Canada) was used for these experiments. 
The direct labeling protocol was chosen since it is a simpler, faster technique and has 
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been shown to work consistently by the University Health Network (UHN) Microarray 
Centre, Toronto, the institution from where the microarray slides were purchased. 
Reverse Transciption: 
Total RNA (10[tg) from each tumor sample or cell line was used to synthesize cDNA 
with 400 units of the Superscript 11 reverse transcriptase enzyme (Invitrogen/Life 
Technologies, Inc., Burlington, CA). Reactions were performed in a buffer containing 
5X first strand buffer, 100pM AncT primer (5'-TTTTTTTTT7TTTTTTTTTTVN-3'), 
0.1 M DTT, 20mM dAGT, 2mM dCTP and Cy3-dCTP/Cy5-dCTP fluorescent dyes. For 
10-20 pg of Qiagen purified total RNA, the reverse transcription reaction volume was 40 
pl. The following volumes were combined on ice. 
8.0 pL 5X First Strand reaction buffer (Superscript 11, Invitrogen) 
1.5 pL AncT mRNA primer (5'-T20VN, 100 pmol/-I) 
3.0 pL dNTP (-dCTP) (6.67 mM each of dATP, dGTP, dTTP) 
1.0 pL 2 mM dCTP 
1.0 pL I mM Cyanine 3 or Cyanine 5-dCTP (NEN) 
4.0 pL 0.1 M DTT 
0.1 - 20 pg RNA (0.1 -0.5 pg mRNA or 10-20 pg total RNA) 
0.5 - 1.0 ng Control RNA 
40 pL dH20 (Sigma) 
All samples analyzed were referenced against Human Universal RNA (Stratagene, 
Vancouver, Canada). This RNA is composed of equal quantities of total RNA from a 
pool of 10 tumor cell lines derived from the mammary gland, liver, cervix, testis, brain, 
skin, B and T- cells, expressing a wide range of genes. This RNA provided a 
denominator for accurate ratio discrimination for microarray analysis. Other studies use 
cell lines derived from normal mucosa 117 or matched normal tissue from the same 
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patient 140 as a reference. Each experiment was performed in duplicate with reciprocal 
fluorochrome labeling. 
The tumor and reference samples were labeled with either Cyanine 3 or Cyanine 5. 
Reactions were kept in the dark, as the dyes are light sensitive. The incubator was 
covered with aluminum foil to create a cover preventing light from photobleaching the 
fluorochromes. The reaction mixture was heated to 65"C for 5 minutes and then placed at 
421C for 5 minutes. 
A semi-quantitative method was used to estimate incorporation. The reactions were spun 
to pull down condensate from the lid of the tubes. I pl, of each Cyanine 5 labeling 
reaction was isolated. The I pL aliquot was run on a standard 1% agarose gel, using only 
5% glycerol as loading buffer, for 30 minutes at 100 V/cm of gel. The gel was exposed 
to a STORM phosphoirnager using the red screen. Using ImageQuant, the amount of 
unincorporated Cyanine5-dCTP vs the DNA smear (densitometry) was measured. A 
yield of 34% or higher incorporation was considered satisfactory. 
Stop Reaction: 
RNA was hydrolyzed by adding 4gl of 50 mM EDTA and 2ý1 of ION NaOH, and 
incubated at 65"C for 20 min. Samples were then neutralized with 4AI of 5M acetic acid. 
A small aliquot of the reaction was pipetted onto pH paper to ensure the solution was 
neutralized. 
Purification: 
Reactions were purified via centrifugation through a 30-Pm micropore column 
(AmiconID Microcong PCR Centrifugal Filter Devices, Millipore, Bedford, MA), to 
remove unbound dye. The Microcong-PCR sample reservoir was inserted into one of the 
two vials provided. 400 pL of nuclease-free water was pipetted into the sample reservoir 
without touching the membrane with the pipette tip. 100 pL sample was added to the 
reservoir and the cap closed. Occasionally, the volumes had to be adjusted to get a final 
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volume of 500 pL. The assembly was placed in a centrifuge, the cap strap aligned toward 
the center of the rotor, and spun at 1000xg for 15 minutes. The column was inspected to 
see that most of the water has gone through the membrane. If water was sitting on the 
membrane, the column was spun again for one minute. When the water had gone 
through, the assembly was removed to a clean tube and 5 pL of nuclease-free water 
carefully added to the reservoir (avoiding touching the membrane surface) and left for 30 
seconds at room temperature. The reservoir was inverted in the tube and spun at 10OOg 
for 2 minutes. Approximately 5-6 pl, of sample was collected. The Cy3 and CyS 
reactions were combined for each set of reference and tumor samples. 
Prehybridisation: 
Arrays were prehybridized for I hour at 371C in 50[il of DIGeasy hybridization buffer 
(Roche, Laval, Qc, Canada) mixed with 5[tl of 10mg/ml yeast tRNA, 5[tl of 10mg/ml 
salmon sperm DNA, and 5pl of 10% BSA in humid hybridization chambers. Slides were 
then washed in double de-ionized water and spin dried prior to hybridization with the 
labeled probes. This step resulted in significantly less background fluorescence. 
Hybridisation: 
Probes were suspended in 80pl of DIGeasy hybridization buffer (Roche, Laval, Qc, 
Canada) combined with 5pl of 10 mg/ml yeast tRNA, 5pl of 10mg/ml salmon sperm 
DNA, denatured for 2 min at 65"C, and then cooled to room temperature. Since the 
microarray slides were designed in pairs (Part A and Part B each containing 9,500 
sequences in duplicate), a "face-to-face" hybridization was used. The two slides that 
make up the pair were faced together, slightly offset to create a lip along one edge. The 
barcodes on the arrays allowed a small space between the slides. The hybridization 
solution was carefully applied along the lip, allowing the solution to evenly occupy the 
space between the slides. This technique allowed a "bubble-free" hybridization. The 
slides were carefully placed into hybridization chambers. These were plastic microscope 
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slide boxes containing a small amount of DIG Easy Hyb solution in the bottom to keep a 
humid environment. Clean plain microscope slides were placed at every second or third 
slide position in the slide box to create rails. Each hybridization chamber held two 
hybridization slides. The lid was carefully placed onto the box and the box then wrapped 
with plastic wrap. The boxes were incubated on a level surface in a 37 'C incubator 
overnight (about 18 hours). 
Washina: 
The hybridization chambers were disassembled and the pairs of slides carefully worked 
free of one another by immersing in IX SSC and sliding the arrays past one another. 
When all of the arrays had been removed from the hybridization chambers, they were 
washed 3 times for 15 minutes each at 50*C in clean slide staining boxes containing pre- 
warmed IX SSC/0.1*/` SDS solution with occasional gentle agitation. After the washes 
were complete, the slides were rinsed twice in room temperature IX SSC (plunging 4-6 
times) and then in O. IX SSC. The slides were spun dry at 500 rpm for 5 minutes in a 
slide box lined with Whatman paper. Arrays were stored in the dark and scanned as soon 
as possible after they are washed. 
3.3 Data coHection 
Slides were scanned using an Axon GenePix 4000A confocal scanner and fluorescence 
intensities quantified using GenePix Pro 3.0 software (Axon Instruments, Foster City, 
CA). A detailed description of this can be found at the website 
http: //www. microarrays. ca/support/Axoný/ý20Scanner. pdf. 
The PhotoMultiplier Tube (PMT) detects the photons that are emitted from the laser- 
excited fluorophores on the microarray. Since increasing the PMT gain increases the 
sensitivity of the PMT, it was important to use optimal PMT gain. Though it was true 
that a higher PMT yielded a brighter image, a brighter image was not always a better 
image. Increasing the PMT increased the noise as well as the signal intensity. If the gain 
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was too high, the noise increased more than the signal, and the signal-to-noise ratio 
decreased significantly. When the PMT was set too low, the process of converting 
photons to electrons was sub-optimal, and the signal-to-noise ratio was low. The best 
signal-to-noise ratio was achieved when the PMT gain was between 500 and 900. 
Although it was recommend that the PMTs be balanced so that the fluorescent intensities 
from both channels were similar, a significant error did not result if the two channels 
were not perfectly balanced. In reality, the signal intensities from both channels cannot 
be identical and subsequent software, which implements a normalization factor, corrects 
this minor imbalance. GenePix Pro 3.0 displays its two single wavelength images at 
different user-configurable colors, and then constructs a red-green-blue ratio image from 
them. It includes three different color schemes to display its ratio images: red-green, 
green-blue, and red-blue. This pseudocolor display provides instant feedback on coarse 
ratios: with a red-green palette, for example, a ratio of I displays as yellow, ratios above 
I show varying shades of red, while ratios of below I show varying shades of green. In 
addition, single wavelength images can be displayed in a number of color palettes: 
grayscale, monochrome, or two different rainbow palettes. 
To measure the intensity of each spot, GenePix Pro 3.0 first assigns a feature indicator to 
it. Feature indicators are grouped into rows and columns to form a Block. Blocks 
themselves are grouped into rows and columns to form an array. It can align and analyze 
the images automatically, for complete hands-free operation. Blocks can be dragged, 
rotated and deformed; feature-indicators can also be dragged and their diameters fine- 
tuned, all with simple mouse or keyboard controls. With a mouse-click or keystroke, 
features can be graphically flagged to mark them as good, bad or absent. Flags are 
exported with all other numerical data. The extracted data is presented in a spreadsheet 
for rapid sorting. Data such as intensity values, ratios and quality measurements are 
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exported for analysis with advanced genomic information systems and is fully integrated 
with web-based genomics databases. 
The Feature Viewer function reports the intensity of the pixels contained within the 
feature-indicator, its associated background intensity level, the precise location of the 
feature-indicator in the analysis array, and gene lDs or names that have been defined for 
each feature. Files are saved as GPR (GenePix Results) files. GenePix Pro 3.0 analysis 
allows extraction of ratio data, production of quality control or interesting genes reports, 
generation of scatter plots or other custom graphs. 
Plots of fold change versus the average intensity were examined to look for 
abnormalities in single array data. It is common to plot a red versus green scatter plot to 
examine for problems; however transforming to fold change versus average intensity 
displayed the data in a more easily viewable form. Plots from all 6 HNSCC cell lines and 
28 OSCC samples were found to be of sufficient quality. 
3.4 Bioinformatics 
The clustering of expression data from the cell lines and tumor samples were performed 
in 3 separate experiments. The data from the 6 cell lines were clustered by BTSVQ. Data 
from the initial 20 OSCC underwent unsupervised hierarchical clustering and BTSVQ. 
Lastly, the full data set from 28 OSCC were combined with the cell line data and 
clustered using BTSVQ. 
Hierarchical clustering of 20 OSCC samnles: 
Hierarchical clustering was performed on the data set from the 20 OSCC. Each 
experiment was first normalized by sub array using Normalize Suite. Low intensity spots 
(<50), ghost spots, and spots with high background to foreground ratios were excluded. 
Duplicate spot intensities were averaged and the ratio of Cy3/Cy5 calculated. Replicates 
were combined by first reversing the Cy3/Cy5 ratio in the reciprocal labeling 
experiments to ensure that the denominator was the tumor sample. Experiments were 
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combined into a "Project file" that could be loaded into the program Cluster. 82 The 
non-nalized mean of ratio values were 1092 transfon-ned and filtered so that only those 
that were present in at least 80% of the samples and that had at least 2 observations with 
an absolute value of 2 in log2 (i. e. at least four fold up or down - regulated) were 
included in the analysis. Unsupervised average-linkage hierarchical clustering was 
applied to both genes and samples using a centered correlation similarity matrix. Genes 
and arrays were median centered. These experiments involved a large number of tumor 
samples all compared to a common reference sample. The analysis needed to be 
independent of the amount of a gene present in the reference sample. This was achieved 
by adjusting the values of each gene to reflect their variation from some property of the 
series of observed values such as the mean or median. This is what is meant by median 
centering of genes. Graphical representation of these data was generated with the 
program TreeView (http: //rana. stanford. edu/software) 
Clustering of samples with BTSVO: 
For experiments using BTSVQ, raw data from the GPR files were loaded into the 
software package. It is helpful to visually analyze data before applying any clustering or 
normalization technique. BTSVQ software has the additional benefit of being able to 
visualize the data in the form of surface plots in three dimensions. Due to outliers or very 
high ratios in the data, these visualistions often appear skewed. Any clustering method 
applied on such data will be biased towards the high values. Thus microarray data is 
generally log-normalized to provide an equal spread between up and down-regulated 
genes. The transformation removes various types of noise, biases and outliers and often 
results in a new range of the data that is easier to work with in further analysis. However, 
the transformation may introduce several distortions and biases, some of which improve 
the information content, while others may eliminate existing valid patterns. Therefore, to 
avoid introduction of biases, BTSVQ provides three important normalizations: log, 
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variance and range. These are applied to the data in sequential order. After each "round" 
of normalisation, the data was visualized using the surface plots. When satifactory 
normalization had occurred, the data was then subjected to clustering using the BTSVQ 
algorithm. This generated a binary tree consisting of clusters or groups of samples at the 
nodes of the binary tree. The expression profiles of the samples in each group were 
readily visualized in the form of a SOM, and profiles easily compared. 
3.5 Statistical analysis of sample clusters 
Sample clusters generated by BTSVQ and hierarchical clustering were subjected to 
Fisher's exact test, chi squared test, Mann-Witney U test and Log-Rank test using SPSS 
for Windows statistical software (version 10.1; SPSS Inc., Chicago, IL, USA). Samples 
clusters were compared to clinical parameters, including sex, age, T and N stage, loco - 
regional recurrence, 2-year disease free survival and overall survival. Statistical 
significance was defined as p.:! ý0.05. Disease free survival was calculated in months and 
comprised the interval between completion of treatment to the date of first recurrence. 
Disease specific survival was calculated from completion of treatment to death due to 
their disease and overall survival from time of completion of treatment to death, 
whatever the cause. Patients with disease recurrence, or who died of their disease or 
other causes, were considered censored. 
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3.6 Results: 
3.6.1 Gene expression analysis of 6 HNSCC cell lines: 
Expression analysis was first performed on six HNSCC cell lines, using cDNA 
microarrays containing 19,200 sequences. Gene expression profiles of the cell lines, 
represented by SOMs, were obtained by BTSVQ analysis. The binary tree is shown in 
Figure 3. Cell lines were classified in two distinct groups (A and B). Cell lines derived 
from the same patient (primary and nodal metastases) were clustered together at the first 
level of the binary tree: UTSCC-60A and 60B in Group A and UTSCC-24A and 24B in 
Group B. Additionally, cell lines derived from tongue carcinomas clustered together 
(Group B). The stage of the two tongue tumors were both T2N I M0, Le between 2-4 cm in 
diameter, with localized neck nodal metastasis (< 3cm) and no evidence of distant 
metastasis. Although all 4 patients from which the cell lines were derived died of their 
disease, the two patients in Group B had the worst overall survival, UTSCC - 24A and 
UTSCC dying of their disease at 9 and 7 months respectively. In Group A, the two 
primary tumors were both T4, Le greater than 6 cm in diameter. On the second level of 
the binary tree, the two cell lines UTSCC-34 (supraglottic larynx) and 60A (tonsil) 
derived from primary tumors clustered together, while UTSCC-9 (tongue) clustered with 
UTSCC-24B (neck metastasis). 
3.6.2 Gene expression analysis of 20 OSCCs: 
The population of 20 samples was representative of the general population with OSCC, 
with a median age of 61 (range 26-83) and a male predominance of 65%. 75% (15/20) of 
the patients had TIII-IV tumors, and 65% (13/20) had regional metastases at 
presentation. None of the patients had distant metastasis. 
Figure 4 shows the binary tree generated by BTSVQ for these 20 tumor samples. On the 
first level of the binary tree, 2 sample clusters were generated. Group I contained 12 
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samples and Group 2 contained 8 samples. The corresponding clinical data for these two 
groups are shown in Table III and statistical correlations are shown Table IV. In Group 
1,10/12 patients were male, 11/12 tumors were stage TIII-IV and 10/12 tumors were 
node positive. The median age was 60.9/12 patients had disease recurrence, 6/12 loco- 
regional and 3/12 distant. The average time to recurrence was 9 months. 7/12 died of 
their disease, 1/12 died of other causes and 4/12 had no evidence of disease at last 
follow-up. The average follow - up in those patients with no evidence of disease was 29 
months. 
In Group 2,3/8 patients were male gender, 4/8 were TIlI-IV stage and 3/8 samples were 
node positive. The median age was 63.5/8 developed loco - regional recurrence at an 
average time of 5 months. 4/8 died of their disease, I was alive with disease at last 
follow - up and 3/12 showed no evidence of disease at last follow - up. The average 
follow - up in those patients with no evidence of disease was 30 months. Group I and 
Group 2 correlated with male gender (P=0.035), TIII-IV stage (P=0.035) and nodal 
metastasis (P=0.035). There were no statistically significant correlations with loco- 
regional recurrence (p=0.55) or 2 year disease free survival (p=0.42). 
Although Group I and 2 did not correlate with prognosis, sample clusters emerged on the 
lower levels of the binary tree that did show trends towards predicting patient outcome. 
In Group 1, one patient (005) split from the main cluster on the second level. This patient 
had a local recurrence and died of disease within 6 months of treatment. On the third 
level, three patients (34,162,3 1) split from the main group. All three patients died, two of 
their disease and one of other causes. On the fourth level, two clusters of four emerged 
each containing advanced staged tumors (Tll[-IV, node positive). The clusters 
composed of samples with strikingly similar expression profiles. In one group of four 
(165,179,111,29), three patients developed disease recurrence (range 7- 25 months) 
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and died of their disease (range 7- 26 months). In the other group of four (40,58,63,79), 
3 patients remain disease free at last follow up (range 12 - 54 months). 
Group 2 contained eight patients that partitioned into two groups of four. One of these 
groups contained all three node positive tumors present in the parent group (86, 
96,147,125). These 3 patients all had recurrence (range 2 to 5 months) and died of their 
disease (5 - 25 months). The other group of 4 contained all non metastatic tumors. Three 
of these patients had no evidence of disease at last follow up (range 10 - 34 months). 
The same dataset was clustered using hierarchical clustering. Following adjustment and 
filtering of the data set as described in the material and methods section, a representative 
subset of 2037 genes was used to cluster samples by median centered unsupervised 
hierarchical clustering. All samples and genes were equally weighted. The dendrogram 
was viewed using Treeview. A representative portion of this pseudo-colour matrix with 
the dendrogram showing how the samples were clustered is shown in Figure 5. The 
samples were split initially into two sample clusters of 10: the red and blue bars below 
the dendrogram delineate these. In the blue group 8/10 tumors were T III-IV and neck 
node positive. 8/10 patients developed disease recurrence, 3 distant and 5 locoregional. 
6/10 died of their disease, one died of other causes and 3 show no evidence of disease at 
last follow-up. In the red group, 7/10 tumors were T III-IV and 5110 neck node positive. 
6/10 patients developed disease recurrence, all locoregional. 5110 died of their disease, I 
was alive with disease and 4 showed no evidence of disease at last follow-up. Correlation 
with age, sex, T and N stage, recurrence or outcome parameters failed to show any 
statistical significance. However, of note, 9/10 samples that were present in the blue 
cluster were also found in Group I from the BTSVQ analysis. Similarly, 7/10 samples 
found in the red cluster were present in Group 2 of the BTSVQ analysis. In the red 
cluster, samples 33 & 39,86 & 96 were found together in the sub classification, while 
sample 29 was classified individually. In the blue cluster, samples 40 & 79,63 & 58, 
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179& 165 were also found in the same clusters in the sub classification. These were the 
same as the clustering found in the lower levels of the binary tree generated by BTSVQ. 
3.6.3 Gene expression analysis of 6 HNSCC and 28 OSCC samples: 
A further 8 OSCC samples underwent expression profiling using the same methods and 
materials as described. This data was collated with the 20 OSCC and the 6 HNSCC cell 
lines. Thus 28 OSCC primary tumor samples and 6 HNSCC cell lines (4 primary and 2 
nodal metastasis) were categorized by comparison of global gene expression profiles 
using cDNA microarrays containing 19,200genes and the BTSVQ data analysis system. 
Patient demographics, TNM staging and follow-up were available on all the tumor 
samples and the 4 primary HNSCC cell lines. This study population was representative 
of the general population with oral/head and neck cancer. The median age was 60, and 
75% (24/32) were male. 72% (23/32) of tumors were T3 or T4.53% (17/32) were node 
positive, while 46% (15/32) were node negative. None of the patients had distant 
metastasis. 
Figure 6 shows the results of the clustering of the 34 samples using BTSVQ. Initially, 
seven samples split from the parent group. On the next level, a reasonably balanced split 
occurred forming two clusters, Group c4 containing 16 samples, and Group P containing 
II samples. The demographics, TNM staging and outcome data for these two groups is 
summarized in Table V. Group a contained one nodal metastasis cell line, which was not 
included in further analysis. 10115 patients were male gender with a median age of 59. 
6/15 tumors were T 1-11 and 12/15 were neck node positive. 12/15 tumors recurred. The 
median follow - up in this group was 12 months, with a 2-year disease free survival of 
21% and 2-year disease specific survival of 42%. In Group P, 9/11 were male with a 
median age of 63.1/11 was T 1-11, and 4/11 neck node positive. 6/11 recurred. The 
median follow up was 24 months, with a 2-year disease free survival of 55% and 2 year 
disease specific survival of 64%. Group a contained a statistically higher proportion of 
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node +ve tumors (p=0.024) compared to Group P. 12/15 patients in Group a recurred as 
compared to 6/11 in Group P, although this was not significant (p=0.085). Group a also 
had a worse 2-year disease free and disease specific survival. Disease free survival was 
statistically significant by log rank analysis of the Kaplan-Meier survival curves 
(p=0.042) (Figure 7). Although disease specific survival was not significant (0.077), the 
same divergence was observed. When the same sample population was stratified for 
disease free survival by N stage, there was no significant correlation by log rank analysis 
(p=0.085). Classification by BSTVQ was therefore a better predictor of disease free 
survival than conventional classification by nodal status. On the next level of the binary 
tree, 2 samples split from Group a and I sample from Group P. 
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3.7 Discussion 
HNSCC represents a clinically heterogeneous group of tumors showing different degrees 
of malignancy. Clinical experience suggests that some carcinomas are destined to remain 
relatively localized, while others will be widely disseminated at an early stage. Our 
current staging system classifies these tumors into broad categories based mainly on 
anatomical considerations. Evidence that further sub typing is possible lies in the fact 
that staged matched tumors show differences in treatment response and outcome. This 
coupled with the fact that overall survival of patients with this disease has not changed 
significantly in the past couple of decades reinforces the need for novel classification 
systems to improve diagnoses and treatment outcome. 
Attempts to find biological markers of tumor progression that may aid classification have 
been limited by the molecular heterogeneity seen within individual diagnostic categories. 
No markers identified so far have proven a sufficiently strong indicator of treatment 
response or prognosis. 125 141 126 However, recent studies have used cDNA microarray 
analysis to classify tumors on global gene expression profiles. These studies fall into two 
main categories, class discovery and class prediction, of which the later has been the 
most reported. By identifying genes which best discriminate sample groups, clusters of 
genes have been identified that predict the known subtype of the disease. These 
64molecular" subtypes can be used to predict patient outcome or treatment response. 
Perou et al characterized variation in gene expression patterns in 65 surgical specimens 
of human breast tumors from 42 different individuals, using complemantary DNA 
microarrays representing 8,102 human genes. 99 These patterns provided a distinctive 
molecular portrait of each tumor. The tumors could be classified into a basal epithelial 
group, an ERBB2-overexpressing group and a normal breast-like group based on 
variation of gene expression. Sets of co - expressed genes were identified for which 
variation in messenger RNA levels could be related to specific features of physiological 
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function. Subsequently, survival analysis on a sub cohort of patients with locally 
advanced breast cancer uniformly treated in a prospective study showed significantly 
different outcomes for the patients belonging to the various groups, including poor 
prognosis for the basal-like subtype and a significant difference in outcome for two 
oestrogen receptor-positive groups. 98 In another study on 117 primary breast tumors, 
DNA microarray analysis and supervised classification was used to identify a gene 
expression signature strongly predictive of a short interval to distant metastases ( "poor 
prognosis" signature) in young patients without tumor cells in local lymph nodes at 
diagnosis. 142 The poor prognosis signature consisted of genes regulating cell cycle, 
invasion, metastases and angiogenesis. In addition, a signature was established that 
identified tumors of BRCAI carriers. These findings provided a strategy to select 
patients who would benefit from adjuvant therapy. 
Alizadeh et al proposed that the variability in the natural history of diffuse large B- cell 
lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, reflected 
unrecognized molecular heterogeneity. ' 00 By microarray analysis, two molecularly 
distinct forms of DLBCL were identified which had gene expression patterns indicative 
of different stages of B- cell differentiation. The molecular classification of these 
tumors on the basis of gene expression revealed previously undetected and clinically 
significant subtypes of cancer. Furthermore, this classification generated patient groups 
that differed in survival after treatment with anthracycline-based multi agent 
chemotherapy regimens. This definition of prognostic groups by gene expression 
profiling, in combination with clinical parameters, may lead to the recommendation that 
some patients with DLBCL receive early bone marrow transplantations upon diagnosis. 
Bittner et al used several analytical techniques to visualize the overall expression pattern 
relationships between cutaneous melanoma tumor samples. Using a matrix of Pearson 
correlation coefficients from a complete pair-wise comparison of all experiments, 31 
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melanoma experiments were displayed as a hierarchical clustering dendrograrn and a 
multidimensional scaling (MDS) plot. 82 A non-hierarchical clustering system was also 
employed (termed cluster affinity search technique: CAST) to define experimental 
clusters. 143 All three analysis systems identified a tight cluster of 19 melanomas. Many 
genes underlying the classification of this subset were differentially regulated in invasive 
melanomas that form primitive tubular networks in vitro, a feature of some highly 
aggressive metastatic melanomas. 144 Thus despite the prevailing view that the 
"taxonomy" of this disease falls in a continuous spectrum lacking discemable entities, 
classification based on gene expression was possible. 145 
Gene expression profiles have also been extensively investigated in prostate cancer. 
Dhanasekaran et al used more than 80 cDNA microarrays to assess gene expression in 
four clinical states of prostate-derived tissues and two distinct reference pools of normal 
specimens. Benign conditions of the prostate clustered separately from malignant 
prostate cancer cell lines or tissues, regardless of the reference pool used. Within the 
prostate cancer cluster, metastatic and clinically localized prostate cancer formed distinct 
subgroups. 
A molecular taxonomy of lung carcinoma was devised from 186 lung tumor samples 
using oligonucleotide arrays corresponding to 12,600 transcript sequences. 103 
Hierarchical clustering defined distinct subclasses of lung adenocarcinoma delineated by 
high relative expression of neuroendocrine genes and type 11 pncumocytes genes. 
Retrospective analysis revealed a less favorable outcome for the adenocarcinomas with 
neuroendocrine gene expression. The diagnostic potential of expression profiling was 
emphasized by its ability to discriminate primary lung adenocarcinomas from metastases 
of extrapulmonary origin. Similarly, global gene expression patterns for 67 human lung 
tumors representing 56 patients were examined using 24,000-element cDNA 
microarrays. 104 Subdivision of the tumors based on gene expression patterns faithfully 
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recapitulated morphological classification of the tumors into squamous, large cell, small 
cell and adencarcinoma. The adenocarcinoma subgroup was further devided into clusters 
that correlated with the degree of tumor differentiation as well as patient survival. 
Studies have been performed looking at correlations between gene expression profiles of 
head and neck cancer and clinical parameters or outcome. Using a set of 906 genes, 
Belbin et al showed it was possible to classify 17 anatomically diverse head and neck 
tumors into two distinct groups that correlated highly with clinical parameters. 113 
Although one group contained more early stage tumors and a lower prevalence of nodal 
metasases at presentation, this group contained patients with a lower 2 year disease- 
specific survival (56% vs 100% p=0.057), and overall survival relative to the other 
group. The molecular classification was a better predictor of disease specific survival 
than clinical - pathological parameters. 
In this study, it was proposed that the phenotypic diversity of head and neck tumors 
might be accompanied by corresponding diversity in gene expression patterns that could 
be captured using cDNA microarrays. Systematic investigation of the gene expression 
patterns might then provide the basis of an improved molecular taxonomy of head and 
neck cancer. The expression patterns of 6 HNSSC cell lines, 20 OSCC tumors and 
subsequently a combination of the 6 cell lines and 28 OSCC were identified using 
microarrays containing 19,200 sequences and two different clustering algorithms. 
BTSVQ analysis has been shown to successfully cluster genes across samples, 
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generating useful and visible data organization. Recently, this method was used to 
cluster gene expression profiles based on the effects of dihydrotestosterone in cell 
culture. 146 BTSVQ analysis is appropriate for studies using clinically heterogeneous 
samples, such as HNSCC, where relevant gene expression patterns may not be identified 
in the first level of the binary tree. 90 
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Additionally, it has been shown to be particularly useful in the identification of 
expression patterns from skewed data or data possessing numerous variable or outliers. 
Several techniques have been used to visualize this highly multi-dimensional data. The 
self-organizing map (SOM) algorithm is an efficient tool for the visualization of 
multidimensional data and has previously been shown to be effective for the exploratory 
analysis of gene expression data. 147 148 SOMs are neural network algorithms widely used 
in data analysis and vector quantization. The algorithm is similar to k-means clustering, 
with the additional constraint that cluster centers are restricted to lie in a two dimensional 
manifold. SOMs show two main characteristics; they realize a quantization of a high- 
dimensional space, as other vector quantization techniques such as LBG 149 and k-means, 
and they exhibit a topological property which allows one to analyze the ordering of 
centroids. Component planes of SOMs are the planes of Voronoi Tessellations, each 
representing a specimen in a microarray experiment. Partitive k-means is a splitting 
hierarchical clustering method. It starts with the whole data set as a single cluster, which 
is partitioned into disjoint subsets D, and D2 . where the inter clusters distanced. is 
maximized. The subsets D, and D2 are further subdivided into D, I&D, 2 and 
D21 & D22 . etc., thus, building a binary tree. 
BTSVQ merges the results of SOM (gene space), and partitive k-means (specimen 
space). The algorithm uses vector quantization and self-organizing capabilities of SOMs 
in finding significant gene centers in gene space (high dimensionality and large number 
of clusters), and the effectiveness of k-means in experiment space (medium 
dimensionality and low number of clusters). The SOM component planes generated by 
BTSVQ represent a biologically intuitive way of representing gene expression data. 
Clusters of differentially expressed genes are easily identified by the color-coded scale, 
which allows easy comparison of expression profiles between samples. Thus the power 
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of BTSVQ lies in the ability to merge two clustering algorithms allowing visual cross- 
verification of sample clusters. 
The initial part of the study involved the generation, clustering and comparison of gene 
expression profiles from the 6 head and neck cell lines. Interestingly, cell lines from the 
same patient were clustered together at the first level of the binary tree; UTSCC- 60 A 
and B in Group A and UTSCC-24A and 24B in Group B. Given the likely clonal 
expansion of cells from the primary tumor to the metastatic node, one would expect this 
observation. Additionally, one would expect cell lines derived from the same anatomical 
site to be found in the same group. Indeed both primary tongue carcinoma cell lines were 
found in Group B. Interestingly, these were both derived from the same stage tumor, and 
the patients had similar survival. The poor prognosis from tongue SCC is related to the 
frequent incidence of regional metastases. Thus despite aggressive therapy with surgery, 
radiotherapy and chemotherapy, many patients will succumb to their disease. Despite the 
primary tumors in Group B having a higher T stage, their overall survival was slightly 
better. Although T stage is not used clinically as an independent predictor of prognosis, 
in most tumors of the head and neck high T stage is associated with a higher incidence of 
metastases and thus poorer outcome. On the second level, UTSSC 34 and 60A clustered 
together, while in Group B, SCC 9 and 24B clustered together. The fact that the 
expression profile of the metastases was less similar to its primary tumor in Group A 
implied that the supraglottic laryngeal and tonsil SCC cell lines had similar gene 
expression profiles and that the metastasis had undergone further genetic de-regulation 
resulting in clustering distant from the parent group. The implication from the further 
sub-classification in Group B, where the primary cell line SCC 9 clustered with the nodal 
metastasis 24 B, is that metastases in tongue cancer have similar genetic deregulation to 
the primary site, even though this may not be primary tumor specific. Perou et al showed 
that in breast cancer, metastasis and primary tumor were as similar in their overall 
57 
pattern of gene expression as were repeated sampling of the same primary tumor, 
suggesting that the molecular program of a primary tumor may generally be retained in 
its metastases. 99 
HNSCCs are a heterogeneous group presenting as tumors of different anatomical regions 
such as the oral cavity, the oro-/hypopharynx, and the larynx. These sub entities show 
different, often contrary, biological and clinical behavior. For example, the potential of 
forming metastases is very low in laryngeal carcinoma, whereas it is quite common in 
pharyngeal carcinomas. It has been shown that the various HNSCC sub entities exhibit 
different genetic alterations, which could explain the different biological behavior of 
these tumors. 150 The tissue microenvironment can markedly change the gene expression 
patterns of cancer cells, and therefore their biological behavior, growth ability and 
potential to metastasize to distant sites 151. Several studies have been performed that 
reveal different genetic alteration patterns depending on the anatomical site in 
HNSCC. 132 152 Using a combination of tissue microarray and fluorescence in situ 
hybridization, Freier et al detected a significantly lower rate of ZNF217 amplifications in 
pharyngeal as compared with oral and laryngeal carcinomas. 153 
Although this pilot study lacked the numbers to reveal statistically relevant associations, 
the principle of classification of head and neck tumors by gene expression profiles rather 
than single genetic alterations was demonstrated. Using these samples as proof of 
principle, it was demonstrated that this type of analysis was able to classify samples into 
meaningful clusters, as the gene expression profiles were associated with clinically 
similar tumor sites and clinical characteristics, and thus provided a platform to which the 
major part of the study could be applied. 
In the second part of the study, gene expression profiles from 20 OSCCs were generated 
and compared. By using a subset of Head and Neck Cancer tumors, the aim was to 
minimize the genetic differences that may be present in anatomically diverse tumors of 
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the head and neck region. Additionally, two different clustering algorithms were used to 
compare and contrast tumor classification, namely BTSVQ and hierarchical clustering. 
This approach revealed a number of novel observations on the pathobiology of OSCC, 
most importantly, the presence of molecular subtypes of OSCC correlating with 
differences in T and N stage. 
BTSVQ analysis identified two clusters from the 20 OSCC dataset. Group I included 12 
OSCC samples and Group 2 was comprised of the other 8 samples. Group I included 
more patients with TIII-TIV category of disease (p = 0.035), lymph node metastasis (P = 
0.035), and also more male patients (p = 0.035). There was a slightly higher recurrence 
(loco-regional and distant) rate and poorer 2-year disease free survival in Group 1, 
although these outcomes were not statistically significant compared with Group 2. 
Although genetic heterogeneity was observed within Groups I and 2, tumors with similar 
clinical characteristics and outcome were classified in distinct branches on subsequent 
levels of the binary tree. This was visualized by observing the patterns seen in the self- 
organizing maps (SOMs) generated for each sample. Thus, by further sub-classification 
of tumor samples, groups with considerable molecular homogeneity were identified. 
From the 12 patients in Group 1, two groups of four patients were identif led in the lowest 
level of the binary tree. One group contained patients with T3-T4 tumors and lymph 
node metastases. Three of these patients had disease recurrence and died of their disease 
within 7-26 months. In this group, patient 29 had no evidence of disease in a follow-up 
time of 24 months. However, this patient had nodal metastasis at disease presentation. 
The clustering of this patient's tumor together with the tumors from patients who 
developed disease recurrence and subsequently died of their disease suggests that this 
tumor may have the potential to recur. This patient is currently being closely monitored 
in a follow-up clinic to help in early detection and intervention. 
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In the other group of four patients, all tumors were T3-T4 and three of four patients have 
no clinical evidence of disease at last follow up. The fourth patient however, died of 
disease at 5 months after surgery. Although his tumor profile clustered with those 
patients with no clinical evidence of disease, visual examination of his tumor profile 
clearly suggests that it is different from the genetic profiles of patients 40,58 and 79. 
Since there is no single established method to estimate the significance of an observed 
degree of relationship obtained by cluster prediction, the same dataset was analyzed with 
a conventional cluster analysis system to investigate whether alternative sample 
clustering revealed a better correlation with clinical parameters and outcome. The 
hierarchical clustering algorithm organizes the experimental samples on the basis of 
overall similarity in their gene expression patterns obtained from filtered data. The 
clustering relationships obtained are summarized in the dendrogram (Figure 5), in which 
the pattern and length of the branches reflects the relatedness of the samples. 92 This 
analysis was based on a subset of 2037 genes generated from adjusting and filtering the 
initial 19,000 genes that had been screened on the array. Although this is a well 
established methods of identifying clinically relevant expression profiles, it has been 
criticized for concentrating on local patterns first, thus loosing the ability to identify 
patterns present at the global level. 89 
The 20 samples were clustered into 2 groups of 10. These two groups failed to correlate 
with either T or N stage, or predict patient outcome. Despite this, there were some 
similarities with the clustering generated from BTSVQ. The observation that 9/10 
samples present in the blue group were also present in Group I implied that hierarchical 
clustering was also able to distinguish tumors of advanced stage without any prior 
biological knowledge of the samples. There were higher numbers of Tl11-IV, node 
positive tumors in the blue group consistent with the BTSVQ clustering in Group 1. 
These patients had a higher recurrence rate, with more patients developing distant 
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metastases, implying a more aggressive tumor biology. Similarly, a slightly higher 
number of patients died of their disease in blue group relative to the red group. 
In addition, there were also some similarities between hierarchical clustering and 
BTSVQ in the sub classification of samples. In Group 2 and the red cluster, samples 33 
& 39 were classified together. Both these tumors were TIV NO derived from the floor of 
the mouth. Similarly, both patients from which tumor samples 86 & 96 were derived 
developed early loco-regional recurrences (5 and 3 months respectively) and died of their 
disease soon after (9 and 5 months respectively). Sample 129, although low stage (TII 
NO), developed a locoregional recurrence within 2 months of treatment and died within 4 
months. This sample was clustered separately in both analyses. In Group 2 and the blue 
cluster, 40 & 79 were clustered together. Both these tumors were advanced stage (TIII- 
IV, NI). Despite this, both patients showed no evidence of disease after a substantial 
follow-up period (24 and 54 months respectively). Similarly, samples 63 and 58 were 
derived from node positive tumors, and both patients developed early loco regional 
recurrence. Samples 165 & 179 were derived from advanced stage tongue tumors (TIII- 
IV) which both developed distant metastasis following treatment (25 and II months 
respectively). Both of these patients died from their disease (26 and 12 months 
respectively). These results suggested that both unsupervised hierarchical clustering and 
BTSVQ were capable of distinguishing advanced stage tumors with poorer outcome 
based on their gene expression profiles and that tumors with similar clinical features and 
outcome could be classified together. However, BTSVQ appeared to have better 
delineation of these groups, based on the statistical correlations. 
By adding further samples to the initial data set, and combining this with the cell line 
data, the aim was to identify clusters of samples that not only correlated with clinical 
parameters, but also had the potential to predict patient outcome. A novel classification 
system must be capable of providing robust information on treatment response and 
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outcome. Therefore, if taxonomy based on gene expression profiles is to be clinically 
useful, it must be better than the current staging system. Correlations of gene expression 
profiles with conventional predictors of outcome such as T and N stage may not 
necessarily enhance the classification of tumors. By acknowledging that clinically 
significant clusters may not initially reveal themselves at the first level of the binary tree, 
this analysis focused on two sample groups that occurred at the second level. Although 
these two subgroups did not include all the samples that were originally analyzed, this 
analysis did highlight that the molecular sub classification of tumors may not be initially 
apparent from the first dichotomous split, and that clinically interesting groups may 
occur at subsequent levels, or indeed on different levels. This was seen in the analysis of 
20 samples, where the groups that emerged on the lowest level of the binary tree showed 
trends towards predicting tumor stage and outcome. 
Group a contained a lower proportion of TIII-IV tumors but a higher proportion of neck 
node positive tumors relative to Group P. In addition, more patients developed disease 
recurrence in Group cE, with a statistically lower 2-year disease free survival (P=0.042) 
and 2 disease specific survival (p=0.077). Thus the molecular classification defined two 
groups: Group a containing "more aggressive" tumors and Group P containing "less 
aggressive" tumors. Interestingly, when T or N stage was used as independent predictors 
of disease free survival, there was no statistically significant correlation (p=0.12, 
p=0.085 respectively). Therefore, the classification of tumors based on gene expression 
profiles was better predictor of outcome than conventional clinical parameters. The 
implication from this classification is that T stage has a less significant impact relative to 
N stage on the likelihood of developing disease recurrence, on 2-year disease free and 2- 
year disease specific survival. In clinical practice, this observation is often seen in head 
and neck cancers, whereby large primary tumors (> Till) have no regional metastases, 
and small primary tumors (<Fll) are associated with large neck lymphadenopathy. The 
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presence of lymph node metastasis has been shown to have a detrimental affect on 
outcome. 154 Interestingly, on the third level of the binary tree, only two patients were 
split from Group a and only I patient from Group P, implying that these two major 
groups were genetically homogeneous and that the analyses was reluctant to partition the 
groups further. 
Recent studies involving gene expression profiling of clinical specimens have had a 
profound impact on cancer research. In many examples, correlations have been made 
between the expression levels of a gene or set of genes and clinically relevant sub 
classifications of tumor subtypes. These results have compounded expectations that true 
molecular classification and sub staging of multiple tumor types may be possible, leading 
to measurable improvements in prognosis and patient management. Overall, these results 
suggest a number of implications for the classification and staging of head and neck 
tumors. Most prominent is that a true molecular staging system, built on either the 
current system or constructed anew, has the potential to additionally refine diagnosis, 
prognosis, and management for patients with this lethal disease. 
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CHAPTER 4: Identification and validation of differentially 
expressed genes. 
4.1 Introduction: 
Gene expression profiling allowed a molecular classification of OSCC and HNSCC cell 
lines. These "molecular maps" were correlated with clinical parameters and outcome. 
The next challenge was to identify the genes that were the "best predictors" of these 
statistical correlations. Since hierarchical clustering of 20 OSCC dataset had not 
identified any statistically significant correlations with clinical parameters or outcome, 
the BTSVQ method for identification of genes was used. BTSVQ selects a unique set of 
genes that best discriminates each sample cluster positioned at each node of the binary 
tree. Selection is based on the gene quantization error (QE). This is the probability of the 
gene having a similar expression value across all samples in that cluster, thus providing a 
measure of the ability of a gene to define a cluster of samples. Genes were ranked from 
"best predictive" to "worst predictive". The lower the QE score, the better predictor of 
the sample cluster. Since Group I correlated with high T and N stage, genes in this 
sample cluster may represent potential biomarkers of advanced stage disease and thus the 
genes that best represented this group were chosen for further study. Additionally, since 
the classification of 34 samples resulted in clusters that were able to predict disease free 
survival, genes were also identified that discriminated Group a and P. 
Furthermore, a subset of the genes representing Group I were selected for validation by 
quantitative real time PCR. This allowed the comparison of individual expression levels 
obtained from an independent technique with those obtained from the microarray 
experiments. The mean levels of expression of the validated genes were compared and 
their power to predict sample clusters investigated. Correlation co-efficients between 
these genes in each group allowed further interrogation of the hypothesis that they were 
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the best predictors of the sample classification generated by the full microarray dataset. 
Additionally, individual gene expression ratios from the 20 sample microarray dataset 
were mapped to respective chromosomal localization, and the localizations of the 6 
validated genes compared with areas of chromosomal gain representing transcriptional 
over activity. 
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4.2 Methods: 
4.2.1 Gene identification: 
Genes that discriminated Group I were identified based on their QE score (Table VI). 
Quantization error does not replace statistical significance, rather, is used to rank-order 
genes based on their potential to cluster samples. Thus QE score provided an accurate 
method of excluding genes with variable expression across samples. Genes were selected 
with a QE score <0.1. This was essentially an arbitrary cut-off point, but served to 
reduce the gene set to a manageable number for investigation. This number was large 
enough to be robust against noise, and small enough to be readily applied in a clinical 
setting. Gene sequences were mapped to Unigene clusters and functions explored to 
evaluate their potential relationships with malignancy. The same cut - off QE score of 
<0.1 was used to identify genes that were the best predictors of Group a and P (Table 
VII). 
4.2.2 Validation by Quantitative Real-Time RT-PCR: 
Based on the in - silico analysis of protein products and mapping information, six out of 
the 23 genes from Group I were selected for expression validation by quantitative real 
time PCR. Real-time chemistries allow for the detection of PCR amplification during the 
early phases of the reaction. Measuring the kinetics of the reaction in the early phases of 
PCR provides a distinct advantage over traditional PCR detection. Traditional methods 
use agarose gels for detection of PCR amplification at the final phase or end-point of the 
PCR reaction. Results are based on size discrimination, which may not be precise and 
vary from sample to sample. While gels may not be able to resolve this variability in 
yield, real-time PCR is sensitive enough to detect these changes. Agarose gel resolution 
is very poor, about 10 fold, while real time PCR can detect as little as a two-fold change. 
Theoretically, there is a quantitative relationship between the amount of starting target 
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sample and amount of PCR product at any given cycle number. Real-time PCR detects 
the accumulation of amplicon during the reaction. The data is then measured at the 
exponential phase of the PCR reaction, the optimal point for detection of product. 
The genes selected for validation were CIDEB, PRKAR2A, ANP32A, GALA76, 
SMARCC2 and CLDNI. The choice of samples to perform this validation on was limited 
because of the quantity of RNA available from each specimen. This meant that 
validation could only be performed on a subset of the total sample size. 
The ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) was used for 
quantitative assessment of expression level of the genes selected for validation. This was 
done using SYBR Green I dye, which allows the quantitative detection of specific 
product accumulation during each PCR cycle. 155 SYBR Green is a dye that binds the 
minor groove of double stranded DNA. As more double stranded amplicons are 
produced, SYBR Green dye signal increases. A CCD camera collects the fluorescence 
emission from the amplified DNA and the data are quantified and analyzed using the 
Sequence Detection System software v. 1.7 (PE Applied Biosystems). 
4.2.3 Genes and Primers: 
cDNA sequences for each gene were selected from the international published databases 
(http: //www. ncbi. nlm. nih. gov/). Primers were designed for optimal hybridization 
kinetics using Primer Express software (version 1.5, PE-Applied Biosystems, Foster 
City, CA, USA) (Table Vill). A full explanation of the details of primer design using this 
software can be found at the website 
http: //www. appliedbiosystems. com/support/tutorials/. 
4.2.4 PCR Amplification: 
Reaction mixtures contained cDNA reverse transcribed from 2ýtg of total RNA from 
each tumor sample or from Human Universal RNA (Stratagene, Vancouver, BC, 
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Canada), 20piM of each primer and 12.5pl of 2X SYBR Green PCR Master Mix (PE 
Applied Biosystems), which includes the SYBR Green I fluorescent dye, 0.5 units of 
AmpErase uracyl-N-glycosylase (UNG) enzyme, 1.25 units of Ampli-Taq Gold DNA 
polymerase, and 200pM of dideoxynucleotides. Amplification conditions were the same 
for all primer sets. Thermal cycling conditions were 50T for 2 min (for UNG enzyme 
activity), 95'C for 10 min, and 40 cycles at 95'C for 15s followed by 60'C for I min. 
Each assay included a human universal cDNA reverse transcribed from Human 
Universal RNA (Stratagene, Vancouver, BC, Canada) and a non-template control. 
Experiments were performed in triplicate for each sample in the same reaction and 
repeated when a coefficient of variation higher than 5% was observed. Target genes and 
the reference gene GAPDH were amplified in the same reaction. 
4.2.5 Quantitative Real-Time RT-PCR Data Analysis: 
Quantification of the expression of the target gene in unknown tumor samples is 
accomplished by measuring the fractional cycle number (Ct) at which the amount of 
expression reaches a fixed threshold and is directly related to the amount of product. The 
threshold line is set in the exponential phase of the amplification for the most accurate 
reading. The precise amount of total cDNA added to each reaction is difficult to assess. 
Therefore, quantified products of the housekeeping gene GAPDH, which maps to 12p 13, 
were quantified as an internal control. The GAPDH gene is frequently used in 
quantitative studies using DNA or RNA. ' 56 This method normalizes the amount and the 
quality of the amplified targets. 157 The relative quantification is given by the Ct values, 
determined for triplicate reactions for test and reference samples for each target and for 
the internal control gene (GAPDH). Triplicate Ct values were averaged and the GAPDH 
Ct subtracted to obtain ACt [ACt = Ct (target gene) - Ct (GAPDH gene)]. ACt values 
were calculated for each tumor and reference sample. Relative expression level was 
determined as 2-'ýAc'. where AACt = ACt (target sample) - ACt (reference sample). For the 
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reference sample, AACt equals zero, and 20 equals one, so the fold change in the 
reference sample equals one, by definition. For the unknown samples, evaluation of 2- 
AAc'indicates the fold change in gene expression relative to the reference sample., 58 The 
values were expressed as N-fold differences in target gene expression. Representative 
plots of the RT-PCR results for GAPDH and the validated gene CLDN I are shown in 
Figure 8. 
4.2.6 Statistical Analysis of Quantitative Real-Time RT-PCR Results: 
Using SPSS for Windows statistical software (version 10.1; SPSS Inc., Chicago, IL, 
USA), relative expression levels obtained from quantitative real-time RT-PCR for the six 
validated genes were subjected to the Mest to identify the differences in expression 
levels of these six genes between Groups I and 2 samples. As multiple comparisons were 
performed on the real-time PCR data from these six genes, Bonferroni correction was 
used to adjust the level of statistical significance to p s' 0.0083. This correction was 
applied to all real-time PCR data analysis. Other studies have used an adjustment based 
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on Dubey's approach to preserve overall significance in multidimensional data. 
In order to determine the predictive value of the six validated genes, an unsupervised 
BTSVQ analysis using the quantitative real-time RT-PCR data was performed. The 
clustering of samples was compared to the binary tree generated from the full microarray 
data set. 
To identify correlations in levels of expression between genes in each sample cluster, a 
correlation matrix was generated using Matlab R12 software (MathWorks Inc., Natick, 
MA, USA) to display the correlation coefficients for the six validated genes in the two 
clinically different groups of samples. The pseudo-color presentation of correlation 
coeff icients represent a visually intuitive way of comparing sample groups. 
An additional feature of Normalise Suite is the Profiler software. Profiler uses updated 
chromosome localization information to generate composite chromosome plots of 
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normalized fluorescence intentsity ratios from selected samples, generating images 
analogous to karyotype profiles from chromosome CGH. Only results for cDNA 
sequences with known cytoband and megabase positions are plotted. To identify up-to- 
date cytoband localizations for the cDNA's housed on the l9k chip, custom software was 
used to parse NCBI UniGene and MapViewer databases. Gene expression ratios were 
thus mapped to their respective chromosomal localizations using Profiler. The 
chromosome locations of the six genes selected for validation were investigated to see if 
they lay in areas of transcriptional over-expression. 
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4.3 Results: 
Gene identification: 
BTSVQ analysis identified a subset of 23 differentially expressed genes with a QE < 0.1 
in Group I samples. These genes are shown in Table VI, along with their respective 
Unigene ID, cytogenetic location and function. From these 23 genes, II were Expressed 
Sequence Tags (ESTs), hypothetical proteins and KIAA sequences with unknown 
function, and 12 were known genes. Of the known genes, a number have known or 
potentially interesting relationships with putative mechanisms of malignancy and 
metastasis. Since these genes were the best predictors of Group 1, these genes may 
represent putative markers of advanced stage tumors and regional metastasis. 
Similarly, BTSVQ analysis identified a subset of 19 differentially expressed genes with a 
quantization error (QE) < 0.1 in Group a samples, and 5 genes in Group P. Gene 
accession number, Unigene ID and function are shown in Table VII. In the cluster of 19 
genes, 13 mapped to unigene clusters, 9 of which were predicted proteins found as EST's 
or hypothetical proteins with no annotated function. In the cluster of 5 genes, 3 mapped 
to unigene clusters with annotated functions. Since Group a and P correlated with disease 
free survival these genes may represent potential biomarkers of outcome for head and 
neck cancer patients. 
Validation: 
6 out of the 23 genes with QE scores < 0.1 that discriminated Group I were selected for 
validation by quantitative real-time RT-PCR. This selection was based on the in-silico 
analysis of protein function, mapping information and association with putative 
mechanisms of malignancy. These genes were CIDEB, PRKAR2A, ANP32A, SAMRCC2, 
CLDNI and GALNT6. Expression of these genes was tested in 14/20 OSCC samples 
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used for microarray analysis. The other cases were not analyzed because of insufficient 
RNA. Of these 14 cases, nine cases (05,29,31,40,58,79,111,165,179) were from 
Group I and five cases (33,39,96,120,147) were from Group 2. 
Relative transcript levels of all genes obtained by quantitative real-time RT-PCR were 
consistent with the microarray data. Samples from Group I had higher expression levels 
of these genes than samples from Group 2. Group 2 samples did not show differences in 
the transcript levels of these six genes; Le., these samples showed transcript levels 
similar to those of human universal RNA. The relative transcript levels of the six genes 
in samples from Groups I and 2, as detected by quantitative real-time RT-PCR, are 
shown in Table IX and Figure 9. 
A comparison between Groups I and 2 of the relative expression levels of the six genes 
obtained from quantitative RT-PCR was performed using the west analysis. A 
statistically significant correlation was observed between CLDNI over-expression and 
the cluster of samples (Group I vs. Group 2; p=0.007) after Bonferroni correction. The 
other five genes were also all over-expressed in Group I samples, as compared to Group 
2 samples. However, over-expression of these five genes was not statistically 
significantly correlated with the clustering of samples in Groups I and 2 after Bonferroni 
correction (level of significance adjusted top _:! ý 0.0083). These data are presented 
in 
Table X. 
BTSVQ analysis of the relative expression levels determined by quantitative RT-PCR 
was applied to cluster the 14 OSCC samples. These results are shown in Figure IOA. 
Interestingly, Group I and Group 2 samples split at the first level of the binary tree, the 
same result previously obtained by BTSVQ analysis of the entire microarray data set. 
These results suggested that the combination of the validated expression levels of these 
six genes was able to predict the clustering of the samples into two groups that correlated 
with advanced stage disease. 
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Pseudo-color correlation matrices were constructed in order to further examine the 
hypothesis that the six genes could play a role in separating Group I and 2 samples. 
These results are shown in Figure 1013. The color map corresponds to the scale of 
correlation coefficients: non-correlated data show as light blue, negative correlation dark 
blue, and positive correlation ranging from yellow to red. The diagonal of the symmetric 
correlation matrix represents self-correlation (r=]. O, dark red). Interestingly, while 
Group I showed high correlation between CIDEB and PRK. 4R2A (r=O. 71), Group 2 
showed a negative correlation (r=-0.2) between these two genes. Similarly, Group 2 
showed high positive correlation of PRK4R2A and GALNT6 (r=0.71), ANP32A and 
CIDEB (r=0.52), and PRKAR2A and SMARCC2 (r=0.53), while Group I showed 
negative correlations (r=-0.44; r=-0.2; r=-0.47, respectively). 
The results of the ideograms generated by the Profiler software for 4 chromosomes are 
shown in Figure 11. The normalized fluorescence intensity ratios per project (sample) are 
shown in yellow, and their average is plotted in red. The black arrows pinpoint the 
localizations of the six genes selected for validation. Since the microarray ratios were 
derived from expression of RNA, the peaks in the traces map to areas of transcriptional 
over - expression. Interestingly the validated genes were located in chromosomal loci 
consistent with transcriptional gain. Additionally, genes PRK, 4R2A and CLDNI mapped 
to distinct relevant regions on chromosome 3: 3p2l. 3 and 3q28-q29 respectively, while 
GALNT6 and SAMRCC2 genes mapped to loci approximately 4Mb on chromosome 12: 
l2qI3.13 and 12ql3-ql4, respectively. 
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4.4 Discussion 
Several studies have used cDNA microarray analysis to identify differentially expressed 
genes involved in development and/or progression in head and neck cancer. Belbin 
identified 375 genes which devided 17 patients with head and neck tumors into two 
clinically distinct subgroups. 113 The selection of genes was based on the ranking of genes 
that best discriminated the two subgroups using an elemental t test. The genes originated 
from diverse functional categories and included genes already associated with neoplastic 
disease states. Of note, genes involved in transport (SLC7A8), RNA processing and 
translation (ribosomal proteins S6 and S19) were up regulated in one group. 
Additionally, genes coding for metabolic enzymes (catalase and xanthine oxidase) and 
genes whose expression is known to be induced by TGF-P (TGF-P inducible early 
response 2, TGF-P activated kinase I b) were also up regulated. 
Using a subtractive library from two HNSCC and six non-nal tissues, Villaret et al used a 
custom built chip to identify 13 independent genes in 16 anatomically heterogeneous 
tumors compared with 22 normal tissues. ' 14 9 of these genes were previously known: 
keratins K6 and K16, laminin-5, plakophilin-1, matrix metal I oproteinase-2, vascular 
endothelial growth factor, connexin 26,14-3.3 sigma, and CaN19. The cytokeratin genes 
K6 and K16 were the most commonly overexpressed genes, a finding consistent with 
head and neck literature. 159 Partial sequencing of four gene elements failed to show any 
homology with a search of the GenBank database; thus they were labeled as novel. 
However, only one of these genes showed significant difference between the average 
expression of the tumor and the control groups. 
Leethanakul et al identified a number of under- and over-expressed genes in matched 
tumor and normal tissues in five HNSCC patients using lazer capture microdissection to 
procure pure samples and arrays containing 588 known cancer genes. " 6 Of note there 
was a significant decrease in the expression of cytokeratins (2-20 fold) in the tumor 
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samples compared with normal, most likely representing loss of differentiation in the 
tumor cells. Additionally, there was a clear increase in cyclin -DI, metal loproteases and 
many growth and angiogenic factors including TGFa, TGFO , EGF, PDGF A chain and 
B chain, different FGF isoforms, HGF and VEGF-C. This supported the conclusion that 
this tumor type secretes factors that are likely to induce epithelial cell gowth in an 
autocrine fashion in addition to promoting the growth of stromal cells and the process of 
neovascularisation. Recently, these authors used bioinformatic tools to retrieve the 
available sequence information from the Head and Neck Cancer Genome Anatomy 
Project (HN-CGAP) database. They compared this information with their data generated 
from cDNA libraries of normal tissue and oral carcinomas of different stages. 160 55 
known genes were identified from this sequence analysis. Of particular interest was the 
sequence match to the monocyte chemotactic protein 3-precursor gene (MCP3), which 
was readily detected in all three cDNA libraries from tumor tissues. MCP3 is a 
chemokine known to induce the production of gelatinase B and chemotaxis of moncytes. 
MCP3 is also known to be produced by tumor cells and its expression in HNSCC may 
play a role in tumor progression. 16 1 To address which of the novel genes were frequently 
expressed in HNSCC, their DNA was used to construct an oral-cancer-specific 
microarray, which was used to hybridise cE- 33 P dCTP labeled cDNA derived from five 
HNSCC patient sets. 162 Initial assessment demonstrated 10 clones to be highly expressed 
(> 2 fold) in the normal squamous epithelium, while in three of the five patient sets, 14 
were highly expressed in the malignant counterpart, thus suggesting that a subset of these 
newly discovered transcripts might be expressed in this tumor type. 115 Similar to these 
experiments, Alevios et al performed large scale gene expression profiling on lazer 
capture microdissected tumor and normal oral epithelial cells analysed on high-density 
oligonucleotide microarrays. 1 15 About 600 genes were found to be oral cancer associated, 
including oncogenes, tumor suppressors, transcription factors, xenobiotic enzymes, 
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metastatic proteins, differentiation markers, and genes that have not been implicated in 
oral cancer. 
A] Moustafa et al used four matched primary normal epithelial and HNSCC cell lines to 
identify 91 up -regulated genes (ratios 2.5 - 200) and 122 down-regulated genes (ratio - 
200 to 2.5) from an Affymetrix array housing 12 530 human genes. 131 Consistent with 
Leethankul et al., the expression of cytokeratins (13 15 17,18), cyclin D2, P-catenin, 
TGF -P, VEGF, FGF and Writ were altered in cancer in comparison with normal cells. 
The expression of 9 selected genes from the cell-cell adhesion and motility group were 
investigated by Western and/or RT-PCR. As expected from the array analysis, Wnt-5a, 
N-cadherin and fibronectin were found to be up-regulated; whereas claudin-7, E- 
cadherin, a-catenin, P-catenin, y-catenin expression were down-regulated. For the first 
time, they confirmed under expression of claudin-7 and connexin 31.1 by microarray, 
western blotting and/or RT-PCR in HNSCC. Claudin 7 is a four transmembrane domain- 
containing protein and is a member of a recently identified family of proteins, the 
claudins. 163 The main function of claudins appears to be critical components of tight 
junctions, and therefore could have important cell adhesion functions in HNSCC. Squire 
et all 17 identified and correlated recurrent gains of 3q and 8q with differentially 
expressed genes located in these chromosomal regions, as detected by comparative 
genomic hybridization (CGH), spectral karyotyping (SKY) and expression array 
analysis, in seven head and neck cancer cell lines and five primary tongue tumors. 
More recently, high-density DNA microarrays and quantitative real-time RT-PCR and 
have identified 45 deregulated genes in oral cancer. 164 A set of well-characterized 
statistical tools which included Wilks' lambda score, error rate estimated from leave-one 
out cross-validation (LOOCV) and Fisher Discriminant Analysis (FDA) were used to 
generate a robust classifier using the identified discriminatory genes. Of the 45 genes 
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identified, six have been previously implicated in oral cancer, and two are 
uncharacterized clones. 
BTSVQ identifies sample clusters based on the analysis of the full data set. This allows 
the identification of clusters based on unfiltered data, thus allowing true global gene 
expression profiling. Genes of significance that represent each cluster are ranked from 
"best predictive" to worst predictive based on their quantization error. This is best 
described as the likelihood of the gene having a similar expression level across all 
samples in that cluster. Because the data has not been previously filtered, this method 
may identify genes with only a small deviation in transcript level from normal. However, 
other studies have shown that genes that are not necessarily expressed over or under a 
certain threshold level may still be important in disease pathogenesis. Thus selection 
based on QE score rather than threshold level may be a more powerful tool in the 
identification of biologically important genes. 
BTSVQ analysis identified 23 differentially expressed genes with QE scores <0.1 in 
Group 1. Of these 23 genes, six genes were selected for validation using quantitative 
real-time RT-PCR. The criteria for selection of these genes for validation were based on 
known mapping information and function, and their putative roles in disease. In order to 
assess the differential expression of these genes in the two clusters and to confirm the 
microarray results, samples from Groups I and 2 from which enough RNA was available 
were included in the validation study. The expression levels of six genes were validated 
using quantitative real-time RT-PCR. 
CIDE-B (cell death-inducing DFFA-like effector B), encodes a cell-death inducing 
protein, and has a role in apoptosis induced by DNA damage. 165 166 Homology is shared 
with the N-terminal region of DIFF (DNA fragmentation factor). The exact nature of the 
molecular mechanisms of CIDE-B-induced apoptosis is unclear. The CIDE-B protein is 
localized in mitochondria and forms homodimers and heterodimers with other family 
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members. Serial deletion analyses suggest that the mitochondria localization signal and 
dimerization interface are overlapped and localized to the 30 amino acid residues at the 
C-terminal region of CIDE-B. Mitochondria localization and dimerization are both 
required for CIDE-B-induced apoptosis. This gene has been found to be down-regulated 
in mucoepidermoid carcinoma. 167 
GALNT6, encodes a member of the UDP-N-acetyl-alpha-D-galactosamine 
polypeptide: N-acetylgalactosaminyltransferase family of enzymes. 168 The levels of 
mRNA expression of three transferases from the same family were quantified in human 
adenocarcinoma cell lines from pancreas, colon, stomach, and breast. 169 Two of the 
GaINAc-transferases, GaINAc-TI and GaINAc-T2, were expressed constitutively and at 
low levels in most or all cell lines examined. A third GaINAc-transferase, GaINAc-T3, 
was differentially expressed. Well-differentiated adenocarcinoma cell lines expressed 
high levels and moderately differentiated cell lines expressed lower levels of GaINAc- 
T3. Thus glycosylation in tumor cell lines may be regulated in part by differential 
expression of GaINAc-transferases and gene expression may be a molecular indicator of 
differentiated adenocarcinoma. 
The SWI/SNF-related, matrix-associated, actin-dependent regulators of chromatin 
(SMARC), also called BRGI-associated factors, are components of human SWI/SNF- 
like chromatin-remodeling protein complexes and are involved in transcription 
regulation and coactivation. Human SMARC genes have been mapped to regions on four 
different human chromosomes, SMARCCI to 3p23-p2l, SMARCC2 to 12ql3-ql4, 
SMARCDI to 12ql3-ql4, SMARCD2 to 17q23-q24, and SMARCD3 to 7q35-q36. 
SMARCCI, SMARCC2, and SMARCDI are assigned to chromosomal regions that are 
frequently involved in somatic rearrangements in human cancers. 170 
ANP32A (acid (leucine-rich) nuclear phosphoprotein 32 family, member A) is involved 
in signal transduction. 171 Interestingly, a sequence identity study showed that the 
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ANP32A gene is identical to the protein named SET, which is encoded by the gene SET 
(SET translocation myeloid leukemia-associated). This gene maps to 9q34 and was 
observed to be fused to the putative oncogene CAN in a patient with acute 
undifferentiated leukemia. 172 
PRK, 4R2A encodes for the regulatory subunit RII alpha of cAMP-dependent protein 
kinase. 173 Other protein kinases have been shown to regulate human head and neck 
squamous cell carcinoma motility, adherence, and cytoskeletal organization. 174 
Finally, CLDNI (Claudin 1), encodes an integral protein component of tight junctions 
and is involved in controlling cell-to-cell adhesion. 163 CLDNI is expressed in cell types 
such as epithelia, endothelia, and perineural cells. The expression of this protein has also 
been observed exclusively in perineuriomas, aiding in the histological classification of 
these tumors. 175 Increased expression of CLDNI has been reported in primary colorectal 
cancers when compared to adjacent non-cancerous mucosa. Furthermore, IHC staining 
showed a high expression of this protein in cancer cells, suggesting a role of this gene in 
colorectal tumorigenesis. 176 CLDNI showed decreased expression in breast tumor cell 
lines, however, no mutations in the promoter or specific exons were found to support its 
under-expression and its role in the breast tumorigenesis process. 177 Interestingly, other 
members of the claudin gene family have also been reported to be over- or under- 
expressed in cDNA microarray studies of head and neck tumors. ' 31 
Quantitative real-time RT-PCR results confirmed the over-expression of the above six 
genes in all the tumor samples from Group I that were used for validation. Group 2 
samples showed no differences in expression, as compared to human universal RNA. In 
the nine tumor samples from Group 1, five of the six genes had increased relative 
transcript levels in comparison to human universal RNA. The PRKAR2A gene only 
showed a slight increase in gene expression. However, studies have suggested that genes 
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showing a relatively small change in transcription may still be functionally important in 
disease etiology and/or progression. 94 
The relative expression levels of the six genes, as detected by quantitative real-time RT- 
PCR, were analyzed using the West. All six genes were significantly correlated with 
sample clusters using a conventional p value of.: 50.05; however, the expression levels of 
five of these genes failed to reach significance after adjusting the level of significance to 
p :50.0083 using Bonferroni correction. The Bonferroni correction is a mathematical 
correction utilized to reduce false positive results derived from statistical analyses where 
multiple comparisons are performed on the same data set. This correction has been used 
to adjust the level of significance in other expression studies. 178 Therefore, after 
Bonferroni correction, CLDNI was the only over-expressed gene significantly correlated 
with the sample cluster containing more advanced stage tumors (p = 0.007). 
In addition, the relative expression levels for the six validated genes detected by 
quantitative real-time RT-PCR were analyzed using BTSVQ. The clustering of samples 
was identical to the clustering obtained previously with the full data Le the 9 samples 
from Group I clustered together and the 5 samples from Group 2 clustered together. 
Furthermore, evidence that these genes were the best predictors of the sample clustering 
came from the correlation matrix generated to identify patterns of correlation between 
genes within each group. Similar correlation matrixes have been used in other studies to 
identify relationships between genes. 179-1 81 The first observation was that the pseudo- 
colors generated to visualize the correlation co-efficients were significantly different, 
implying that correlations between paired genes could also be used to dichotomise the 
two groups. The second observation that the correlation co-efficients were positively and 
negatively correlated between groups further reinforces the case for these genes ability to 
predict sample classification. 
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The ideograms generated from the Profiler software demonstrated that the 6 genes were 
located on cytogenetic bands with high transcriptional activity. The genes PRKAR2A and 
CLDNI map to distinct relevant regions on chromosome 3: 3p2l. 3 and 3q28-q29 
respectively. CGH studies indicate that these two regions are amplified in head and neck 
cancer. 182-184 Gain of 3q is one of the earliest genetic markers for invasion and metastasis 
and correlates with poor prognosis. ' 83 This region (3q26.1-29) is also reported as the 
smallest recurrent chromosomal region of high-level amplification in OSCC using 
CGH. 132 
The GALNT6 and SAMRCC2 genes, mapping to 12q 13.13 and 12q I 3-q 14, respectively, 
are approximately 4Mb apart. Gains in this chromosomal region are correlated with a 
poor prognosis and metastasis in lung 185 and head and neck cancer patients. 186 In 
addition, recurrent DNA copy number loss of 12q with a minimal common overlapping 
region at 12ql2-ql3 was reported in adenoid cystic carcinoma. 187 The concomitant 
differential expression of these genes suggests that this region may have an important 
role in the prediction of prognosis. 
BTSVQ identified several genes of interest that were the best predictors of Group a and 
0 obtained from the classification of 34 samples. Prosaposin is a multifunctional protein 
that has been reported to be secreted by breast cancer cel IS188' induce extracellular signal- 
regulated kinases and sphingosine kinase activity, increase DNA synthesis, and prevent 
cell apoptosis. 188 189 Studies have suggested its putative role in eliminating barriers to 
tumor metastasis by facilitating hydrolysis of membrane glycolipids. 188 CD40 is a M, 
45,000 to 50,000-glycoprotein member of the tumor necrosis factor receptor superfamily 
expressed on the surface of a variety of cells. Podner et al. showed CD40 expression on 
the cell surface of 7 HNSCC cell lines and provided putative evidence for its function in 
cell growth regulation. 190 In OSCC, loss of polarised expression of CD40L and 
maintained expression of CD40 might be involved in turnorgenesis and immune evasion 
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191 
, and expression in metastatic lung cancer has raised the possibility of CD40 as a 
prognostic marker and an indicator of advanced disease. 192 In a Phase I study, 
recombinant CD40 ligand showed encouraging antiturnoural activity in a patient with 
advanced laryngeal cancer. 193 Up-regulation of Bcl-2 expression in endothelial cells that 
constitute tumor microvessels has been shown to enhance intraturnoral microvascular 
survival and density, and accelerate tumor growth. 194 Neoplastic conversion of human 
urothelial cells has been shown in vitro by overexpression of H202-generating 
peroxisomal fatty acyl CoA oxidase'95. An increase in the expression of cyclin GI during 
sequential development of liver cancer has been observed, and therefore may play an 
important role in tumor progression in oral cancer 196 
Many clinical studies have correlated alterations in expression of individual genes with 
clinico - pathological criteria and outcome, often with contradictory results. 141 197-203 
Surprisingly none of these more "classical" markers were present in the set of marker 
genes identified by BTSVQ. This could be due to the fact that gene expression was 
determined at the level of transcription in microarray experiments, whereas most of these 
studies measured protein levels. However, it is more likely that these genes in isolation 
have limited predictive power, which highlight an approach based on many genes. 
Additionally, the absence of genes already associated with head and neck cancer was 
perhaps not surprising: (a) some genes, such as cyclin DI was not on the array used in 
this study; and (b) because this study specifically addressed differences in gene 
expression between the primary tumors themselves, one would not necessarily expect to 
see genes identified previously by comparing tumor cells with corresponding "normal" 
cells. Thus, identification of a cluster of genes with distinct biological functions, whose 
combined expression profile correlates with disease, may prove a more powerful tool in 
identifying clinically relevant biomarkers, as compared to single gene studies. The 
mechanisms by which alterations in the activities of these genes may influence tumor 
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growth, development and metastasis may include over-expression of normal gene 
products, gene amplification or mutation. 
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4.5 Conclusions 
Novel classification systems of head and neck cancer are crucial to improve patient- 
specific treatment strategies and outcomes. These findings were consistent with recent 
data that link classification based on a gene or set of genes to clinically relevant sub- 
classifications of tumors. 88 94 113 116 Further investigation of these genes is required to 
ascertain their validity and potential use as diagnostic markers or markers of disease 
progression in head and neck cancer. Studies such as these will allow identification of 
gene clusters that are relevant to the diagnosis and prognosis of patients with head and 
neck cancer, and to design disease-specific gene arrays. The use of such "onco-chips" 
may ultimately result in improvements in patient outcome due to the development of 
more tailored therapeutic strategies for the treatment of head and neck cancer. 
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A schematic of a single SOM component plane representing the gene expression profile 
of a single sample. Component planes are the planes of Voronoi Tessellations. Each 
hexagonal unit represents a gene (gene ID is seen within each heaxagon) to which a color 
is assigned. Red represents up-regulation, blue represents down-regUlation, and yellow 
represents no change in expression. Genes with similar expression are clustered 
together. 
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BTSVQ clustering of gene expression profiles from 6 HNSCC cell lines on the basis of 
19,200 genes. A Self Organising Map (SOM) represents each sample. Comparison of 
expression profile between tumors is easily visualized by observing the color patterns. 
Samples with similar expression profiles are clustered at the nodes of the binary tree. 
Group A and B represent clusters containing primary and metastasis from the sarne 
patient. Group B contains all tongue carcinomas. 
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BTSVQ clustering of expression profiles from 20 oral carcinomas based oil 19,200 
genes. Each Self Organizing Map (SOM) represents the expression profile of a tumor. 
Composite profile represents clusters of genes that are similarly under- or overexpressed. 
Group I and 2 correlated with advanced stage tumors. DOD, died of disease-, NED, no 
evidence of disease at last date of follow-up. 
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Figure 5 
Unsupervised hierarchical clustering of 20 OSCC based on the expression of 2037 
genes. A representative portion of the treeview image is shown, with the gene ID's 
shown on the right side of the image, and sample clustering dendrogram shown above. 
Over-expressed genes are red, under-expressed genes green. Sample were devided into 
two groups of 10 (red group and blue group). In the blue group, 9/10 samples were 
found in Group 1, and in the red group, 7/10 samples were found in Group 2 of the 
BTSVQ clustering of the same clataset. 
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Figure 6 
Clustering of 34 samples by BTSVQ. Group cc &0 correlated with nodal status and 
disease free survival. 
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Figure 7 
Disease-free (A) and disease-specific (B) Kaplin-Meier survival graphs for Group a 
(bottom line) and Group 0 (top line). + censored patients 
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Representative product accumulation plots obtained from quantitative real-time RT-PCR 
for GAPDH (A) and CLDN I (B) 
105 
kI 
0Z4 't S tü 1.14 le, li '0 . '. ' U . 14 -8 30 SýI 34 !4" 44 
Cyt §0 
-0 ,-.. -S .#* 
'4 40 
Figure 9 
Group 1 Group 2 
20 
18 
16 13 ANP32A 
14 0 PRKAR2A 
12 OCLDNI 10 
8 CICIDES 
6- mSMARCC2 
" 
'I 4- - 13GALNT6 i '5 2- - M 
0 - I 
U') 
(D 
(n ý Cý CD (Y) U') 
C4 (0) -t W) r- QD 
C) 
r- 
4.0 r- 
0) v 
0 (n CY) 
(14 Cl) to) 
(ý 
0 
00000ýý 
..... ID ID 
ý 
0 
a V- 
"I 
ýSW 
to 41 
Tumorsamples 
Comparison between the expression levels obtained by quantitative real-time PCR for 
the six genes in the samples from Groups I and 2. Over-expression of these genes is 
observed in samples from Group I but not in samples from Group 2, consistent with 
microarray results. 
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(A) BTSVQ analysis was applied to cluster all samples using relative transcript 
expression levels as determined by quantitative RT-PCR- The binary tree clearly shows 
that the six genes are highly predictive, as all samples from Group I (blue) are split from 
Group 2 (green) samples at the first level of the tree. (B) Pseudo-color correlation matrix 
Group I samples and Group 2 samples. The color map corresponds to the scale of 
correlation coefficients: non-correlated data show with a coefficient of zero (light blue), 
negative correlation dark blue, and positive correlation ranging from _1'ellow 
to red. The 
diagonal of the symmetric correlation matrix represents self-correlation and thus is equal 
to one (dark rea). The numerical correlation co-efficients are shown below. 
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Figure II 
The results of the ideograms generated by the Profiler software for 4 chromosomes. The 
non-nalized fluorescence intensity ratios per project (sample) are shown in yellow, and 
their average is plotted in red. The black arrows pinpoint the localizations of the six 
genes selected for validation. These are located on bands of high transcriptional gain. 
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TABLES: 
Table I. 
Clinical data of patients from whom cell lines were derived. 
Cell line Age/Sex Tumor site TNM Grade Outcome 
stage (Follow-up time) 
UTSCC-9 81/M Tongue SCC T2NIMO I DOD (7) 
UTSCC- 41/M Tongue SCC T2NMo H DOD (9) 
24A 
UTSCC- 41/M Neck node from 24A T2N, Mo 11 
24B 
UTSCC-34 63/M Supraglottic Laryngeal T4NOMO DOD (10) 
SCC 
UTSCC- 59/M Tonsil SCC T4NIM0 DOD(16) 
60A 
UTSCC- 59/M Neck node from 60A T4NIMO 
60B 
SCC: squamous cell carcinoma 
TNM: Tumor, Node, Metastasis 
Follow-up time is given in months and corresponds to time between date of surgery and 
patient's death. 
DOD: died of disease 
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Table I/. 
Patient demographics and tumor details 
ID Age Sex T Stage N Stage Recurrence Outcome 
79 44 M I I Loc/Reg NED 
111 46 M I I Loc/Reg DOD 
34 58 M 1 0 Distant DOD 
58 58 M 0 1 Loc/Reg NED 
63 59 M I I Loc/Reg DOD 
39 60 F 1 0 Loc/Reg AWD 
165 62 F I I Distant DOD 
29 64 M I I None NED 
40 66 M I I None NED 
162 74 F 1 0 None DOC 
96 75 m I I Loc/Reg DOD 
45 37 F 1 0 None NED 
2 60 m I I Distant DOD 
85 64 M 0 0 None DOC 
25 65 m 1 0 None NED 
193 75 m 0 0 None DOC 
19 48 m 1 0 Loc/Reg DOD 
131 56 M 1 0 None NED 
26 66 m 0 0 Loc/Reg DOD 
179 69 M I I Distant DOD 
125 26 F 0 1 Loc/Reg DOD 
31 48 M I I Loc/Reg DOD 
147 50 F 0 1 None NED 
86 53 m 1 0 Loc/reg DOD 
120 67 F 0 0 None NED 
33 70 m 1 0 None NED 
5 74 M I I Loc/Reg DOD 
129 83 F 0 0 Loc/Reg DOD 
T stage, 0= 1-11,1 = III-IV 
N stage, 0= NO I= NI, N2, N3 
Loc/Reg = Locoregional recurrence 
DOD, Died of disease; DOC, Died of other causes; AWD, Alive with disease; NED, No 
evidence of disease at last follow up 
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Table III 
Description of patients in GroupI and 2 as defined by BTSVQ analysis of expression 
data from 20 OSCC samples, clinical and histopathologic data, local or distant 
recurrence and outcome. 
Case 
number 
Age/Sex Tumor 
site 
T 
category 
N 
category 
Recurrence 
*(months) 
Outcome 
*(months) 
Group 1 
34 58/M FOM 3 0 Distant (11) DOD (11) 
40 66/M FOM 3 1 No NED (24) 
58 58/M FOM 2 1 Loc/Reg (10) NED (12) 
63 59/M FOM 3 1 Loc/Reg (2) DOD (5) 
162 74/F Tongue 4 0 No DOC (26) 
005 74/M Tongue 4 1 Loc/Reg (6) DOD (6) 
79 44/M FOM 4 1 Loc/Reg (4) NED (54) 
165 62/F Tongue 4 1 Distant (25) DOD (26) 
179 69/M Tongue 3 1 Distant (11) DOD (12) 
31 48/M Tongue 4 1 LoclReg (27) DOD (29) 
III 46/M FOM 4 1 Loc/Reg (7) DOD (7) 
29 64/M Tongue 4 1 No NED (24) 
Group 2 
86 53/M Tongue 3 0 Loc/Reg (5) DOD (9) 
96 75/M FOM 4 1 Loc/Reg (3) DOD (5) 
120 671F Tongue 2 0 No NED (34) 
129 83/F Tongue 2 0 Loc/Reg (2) DOD (4) 
33 70/M FOM 4 0 No NED (20) 
39 60/F FOM 4 0 Loc/Reg (10) AWD (10) 
147 50/F Tongue 2 1 No NED (35) 
125 26/F Tongue 2 1 Loc/Reg (2) DOD (25) 
FOM: Floor of Mouth 
N category, 0= NO, I=N1,2a, 2b, 2c, 3 
Loc/Reg = Locoregional recurrence 
No= No recurrence 
DOD, Died of disease; DOC, Died of other causes; AWD, Alive with disease; NED, No 
evidence of disease at last follow up. 
*: time to recurrence and outcome in months. 
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Table IV. 
Correlation of tumor characteristics, patient demographics and outcome based on 
BTSVQ defined groups from 20 OSCC samples. 
Group 1 Group 2 p value 
Sample Size 12 8 
Male gender 10 3 0.035a 
Median Age 60 63 0.62 b 
T stage 
1-11 1 4 0.035a 
III-IV 11 4 
N stage 
Node -ve 250.035a 
Node +ve 10 3 
Recurrence 950.55a 
2-year disease-free survival 58% 62% 0.42' 
Node -ve: absence of lymph node metastasis 
Node +ve: presence of lymph node metastasis 
'Fisher's exact test 
b Mann-Whitney U test 
'Log-Rank Test 
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Table V. 
Comparison of patient demographics, survival and tumor characteristics between the two 
groups defined by BTVSQ from the analysis of 34 samples. 
Group a Group P 
Sample Size, n 16 11 
Male gendern 10* 9 0.39a 
Median Age 59* 63 0.42 b 
T stage, n 
1-11 6 1 0.79' 
III-IV 9 10 
N stage, n 
Node -ve 3 7 0.024' 
Node +ve 12* 4 
Recurrence, n 12* 6 0.085 
Median follow-up, months 12* 24 
2-year disease-free survival 21 %* 55% 0.042f 
2-year disease-specific survival 42%* 64% 0.077f 
"Chi-square test 
b Mann-Whitney U test 
* Calculated from 15 patients 
f Log-Rank Test for the comparison of Kaplan-Meier survival curves. 
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Table VI 
Significant deregulated genes identified by BTSVQ analysis of 20 OSCC samples. 
Validated genes are in bold. * Function not described in the available sources of 
information on genes and proteins 
Unigene Gene symbol/name Cytogenetic Function 
ID location 
Hs. 188614 EST Unknown Unknown 
_ Ils. 142442 HPI-BP74 I p3 6.13 DNA binding activity, nucleosome 
assembly 
Fls. 13144 ORMDL2/ORMl-like2 12ql3.13 *Known or inferred 
_ Hs. 271692 EST Unknown Unknown 
[Is. 285013 ANP32AIacid (leucine-rich) 15q22.33 Intracellular signaling cascade 
nuclear phosphoprotein 32 family, 
member A 
Hs. 7327 CLDNI/claudin I 3q28-q29 Cell-cell adhesion in epithelial 
endothelial cells 
Ils. 42722 EST Unknown Unknown 
t1s. 365523 PRKAR2AIprotein kinase, cAMP- 3p2l. 3 c-AMP dependent protein kinase, 
dependent, regulatory, type 11, intracellular signaling cascade 
alpha 
11s. 343244 APIG2/adaptor-related protein 14q 11.2 Transport of ligand-receptor 
complex 1, gamma 2 subunit complexes from the 
plasma membrane or from the trans. 
Golgi network to lysosomes 
Ils. 187505 EST Unknown Unknown 
tls. 75360 CPE/carboxipeptidase E 4q32.3 Cleaves C-terminal amino acid 
residues and is involved in 
neuropeptide processing 
Ills. 151678 GALNT6/UDP-N-acetyl-alpha-D- 12qI3.13 Catalyze 
galactosamine: polypeptide N- acetylgalactosaminyltransferase 
seetylgalactosaminyltransferase 6 reactions 
Ils. 42743 Hy thetical Ilq2I Unknown 
Fls. 193698 EST Unknown Unknown 
_ tls. 12294 EST Unknown Unknown 
_ "s. 236030 SAIARCC21SWIISNF related, 12qI3.3 Transcription regulation and 
matrix associated, actin dependent coactivation, chromatin remodeling 
regulator of chromatin, subfamily 
c, member 2 
11s. 12144 KIAA1033 12q24.11 Unknown 
_ Hs. 31532 flomo sapiens mRNA; cDNA 
DKFZp434FI72 (from clone Unknown Unknown 
DKFZp434FI72) 
Hs. 82001 PKD2/polycystic kidney disease 2 4q2l-q23 Calcium-activated intraccilular 
(autosomal dominant) calcium release channel in vivo 
Hs. 156016 KIAA0140 Unknown Unknown 
_ Ils. 49391 c2 I ort9 I /chromosome 21 open 2lq2l. l Unknown 
reading frame 91 
Hs. 138485 EST Unknown Unknown 
_ Hs. 288835 CIDEB/cell-death inducing DFFA- 14q 11.2 Cell death, induction of apoptosis 
like effector B by DNA damage 
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Table Vil 
Selection of genes with a QE score <0.1 that discriminated Group a (Cluster 1) and 
(Cluster 2) generated by BTSVQ analysis of 34 samples. 
GeneBank 
accession no. 
Unigene ID Gene annotation 
Cluster I W90717 Hs. 177386 EST 
R49227 Hs. 13702 EST 
N34216 Hs. 33519 EST 
R62994 Hs. 78575 Prosaposin 
N48062 Hs. 13809 FLJ10648 
N74025 Hs. 251415 Human Type I iodothyronine- 
deiodinase 
N69121 In multiple clusters 
AA131920 Hs. 214368 
R98073 Hs. 172382 
R06909 Hs. 269029 
R61019 Hs. 1001855 
H00517 In multiple clusters 
W88532 Hs. 254562 
AA203290 Hs. 25648 
W93973 Hs. 77572 
EST 
FLJ20001 
EST 
EST 
EST 
Tumour necrosis factor receptor 
superfamily, member 5 
BCL2/adenovirus El B 19kD- 
interacting protein I 
Cluster 2 H65659 Hs. 100009 Human peroxisomal acyl-CoA 
oxidase 
H53489 Hs. 1012 Complement component 4-binding 
protein a 
W37850 Hs. 79101 Cyclin GI 
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Table Vill 
Primer sequences used for validation by quantitative real-time RT-PCR. 
Gene Primers Forward (F) and Reverse (R) 
CIBEB F- 5'-GTCCTCTGATCCCCTCGTGA-3'1 R- 5'-GGGATGTGAGGCGTTATGCT-3' 
PRKAR2A F- 5'-AAAGGATGGGCAGAGGTTCA-3'1 R- 5'-GGGCCTTCAGAAGCAAAGTG-3' 
ANP32A F- 5'-GGGACATTCCCCATCTCTCA-3'1 R- 5'-CCCACCACCATCTGTGAAGG-3' 
SMARCC2 F- 5'-GTGGCTCCAGCCTCTGTAGT-3'1 R- 5'-GTTCAGAAGGGCCCAAACTT-3' 
CLDN1 F- 5'-GCCCCAGTGGAGGATTTACT-3'1 R- 5'-GCAATGTGCTGCTCAGATTC-3' 
GALNT6 F- 5'-CACCGATGGAAGAGACCATT-3'1 R- 5'-TCCCTACTTTGGGAGCCTCT-3' 
GAPDH F- 5'-GGCGACGCAAAAGAAGATG-3'1 R- 5'-CCGTTGACTCCGACCTTCAC-3' 
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Table IX 
Relative expression levels as detected by quantitative real-time RT-PCR for the six genes 
in samples from Group I and 2. 
Case 
number 
Genes 
Group I SMARCC2 CIDEB CLDNI ANP32A GALNT6 PRKAR2A 
5 2.235 2.657 7.996 0.330 12.550 2.143 
29 1.459 2.629 12.668 4.469 2.789 0.959 
31 1.658 2.403 6.590 2.151 3.125 2.878 
40 1.385 1.310 2.958 4.680 2.234 3.506 
58 1.375 1.098 5.207 1.510 18.507 1.109 
79 2.245 1.847 1.230 4.659 7.308 2.534 
111 1.010 4.806 4.815 1.575 2.479 6.498 
165 3.149 1.664 5.159 1.607 4.287 1.399 
179 1.687 1.177 5.205 1.723 7.310 2.310 
Mean 
*SD 
1.800 
0.645 
2.176 
1.155 
5.758 
3.233 
2.522 
1.633 
6.732 
5.545 
2.592 
1.686 
Group 2 
33 1.052 1.085 0.712 1.046 1.240 1.1ý1 
39 1.046 1.046 0.740 0.840 1.084 0.949 
96 1.051 1.026 1.280 0.450 1.060 1.043 
120 1.215 1.043 1.057 1.052 1 1.250 1.337 
147 1.206 1.222 0.949 1.049 0.900 1.035 
S 
ean 
c 
ý 
*SD 
1.114 
0.088 
1.084 
0.079 
0.947 
0.235 
0.887 
0.260 
1.106 
0.144 
1.105 
0.150 
*SD: Standard Deviation 
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Table X. 
Correlation between clustering of samples in Groups I and 2 and relative expression 
levels of genes, as detected by quantitative real-time RT-PCR. 
Category II Genes III 
CLDNI SMARCC2 GALNT6 ANP32A CIDEB PRKAR2A 
_Groupl 
vs. Group 21 p--0.007* p=0.013 p=0.016 p7ý0.0 17 p=0.022 rF--0.077 
Adjusted p value using Bonferroni correction: p.:! ý0.0083. 
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